17 June 2022
EMA/CHMP/253483/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 19-22 April 2022

Vice-Chair: Bruno Sepodes, deputising for the Chair Harald Enzmann

Disclaimers

Some of the information contained in this this set of minutes is considered commercially confidential or sensitive and therefore, not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Vice-Chairperson opened the meeting by welcoming all participants. Due to the coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Luxembourg gave a PROXY to Austria on 21.04.2022. Romania gave a PROXY to Austria on 22.04.2022.

1.2. Adoption of agenda

CHMP agenda for 19-22 April 2022

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 21-24 March 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 11 April 2022.

The CHMP adopted the minutes of the March Plenary meeting as well as the minutes from the April PROM meeting.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. trastuzumab - EMEA/H/C/005880

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Oral explanation

Action: Oral explanation to be held on 21 April 2022 at 15:30

An oral explanation was held on 21 April 2022. The presentation by the applicant focused on the quality and clinical data in support of the application.

2.1.2. trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Oral explanation

Action: Oral explanation to be held on 21 April 2022 at 15:30

List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

An oral explanation was held on 21 April 2022. The presentation by the applicant focused on the quality and clinical data in support of the application.

2.2. Re-examination procedure oral explanations

2.2.1. Aduhelm - aducanumab - EMEA/H/C/005558

Biogen Netherlands B.V., Alzheimer's disease

Scope: Oral explanation

Action: Oral explanation to be held on 20 April 2022 at 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

The CHMP noted the withdrawal of the re-examination request.

See 3.5

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Actrapid - insulin human - Article 58 - EMEA/H/W/005779

Novo Nordisk A/S, treatment of diabetes mellitus

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 22 April 2022.

The summary of opinion was circulated for information.

3.1.2. Filsuvez – birch bark extract - Orphan - EMEA/H/C/005035

Amryt Pharmaceuticals DAC, Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

Oral explanation held on 24.03.2022. List of Outstanding Issues adopted on 27.01.2022, 11.11.2021. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.3. Insulatard - insulin human - Article 58 - EMEA/H/W/005780

Novo Nordisk A/S, treatment of diabetes mellitus

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 22 April 2022.

The summary of opinion was circulated for information.

3.1.4. Lunsumio - mosunetuzumab - Orphan - EMEA/H/C/005680

Roche Registration GmbH, refractory follicular lymphoma (FL)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.03.2022. List of Questions adopted on 25.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that mosunetuzumab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 April 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.5. Pirfenidone AET - pirfenidone - EMEA/H/C/005873

Alfred E. Tiefenbacher (GmbH & Co. KG), Pirfenidone AET is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Esbriet

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 April 2022.

The summary of opinion was circulated for information.

3.1.6. Tabrecta - capmatinib - EMEA/H/C/004845

Novartis Europharm Limited, treatment of non-small cell lung cancer (NSCLC)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by majority (21 out of 31 votes) together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that capmatinib is a new active substance, as claimed by the applicant.

The divergent position (Thalia Marie Estrup Blicher, Christophe Focke, Christian Gartner, Armando Genazzani, Ilko Getov, Andrea Laslop, Outi Mäki-Ikola, Jan Müller-Berghaus, Robert Porszasz, Martina Weise, Ingrid Wang) was appended to the opinion.

The Icelandic CHMP member agreed and the Norwegian CHMP member did not agree with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. asciminib - Orphan - EMEA/H/C/005605

Novartis Europharm Limited, treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. dimethyl fumarate - EMEA/H/C/005963

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. molnupiravir - EMEA/H/C/005789

Treatment of coronavirus disease 2019 (COVID-19)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.4. lenacapavir - EMEA/H/C/005638

treatment of human immunodeficiency virus type 1 (HIV-1) infection

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. maribavir - Orphan - EMEA/H/C/005787

Takeda Pharmaceuticals International AG Ireland Branch, treatment of cytomegalovirus (CMV) infection

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.10.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. fosdenopterin - Orphan - EMEA/H/C/005378

Accelerated assessment

Comharsa Life Sciences Ltd, treatment of molybdenum cofactor deficiency type A

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. ranibizumab - EMEA/H/C/005019

treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation (CNV)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. surufatinib - EMEA/H/C/005728

treatment of progressive neuroendocrine tumours

Scope: List of outstanding issues; Letter by the applicant dated 14 April 2022, requesting an extension to the clock stop to respond to the list of outstanding issues to be adopted in April 2022.

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

3.2.9. sorafenib - EMEA/H/C/005921

treatment of hepatocellular carcinoma and renal cell carcinoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. ranibizumab - EMEA/H/C/005610

treatment of neovascular age-related macular degeneration in adults

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.11. eladocagene exuparvovec - Orphan - ATMP - EMEA/H/C/005352

PTC Therapeutics International Limited, treatment of aromatic L-amino aciddecarboxylase (AADC) deficiency

Scope: List of outstanding issues

Action: For information

List of Outstanding Issues adopted on 05.11.2021, 16.04.2021. List of Questions adopted on 20.05.2020.

The CHMP was updated on discussions at CAT and on an oral explanation, which took place at the April CAT meeting.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee endorsed a 3rd list of outstanding issues with a specific timetable, as adopted by CAT.

3.2.12. efgartigimod alfa - Orphan - EMEA/H/C/005849

Argenx, treatment of generalised Myasthenia Gravis (gMG)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. olipudase alfa - PRIME - Orphan - EMEA/H/C/004850

Accelerated assessment

Genzyme Europe BV, treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients disease-modifying enzyme replacement therapy for long-term treatment of non-Central Nervous System

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.14. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited, treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021, 16.09.2021, 25.02.2021. List of Questions adopted on 23.07.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 4th list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. ublituximab - EMEA/H/C/005914

treatment of relapsing forms of multiple sclerosis (RMS)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. dimethyl fumarate - EMEA/H/C/005950

treatment of multiple sclerosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. sirolimus - Orphan - EMEA/H/C/005896

Plusultra pharma GmbH, Treatment of angiofibroma associated with tuberous sclerosis complex

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. tremelimumab - EMEA/H/C/004650

treatment of adults with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. parsaclisib - Orphan - EMEA/H/C/005893

Incyte Biosciences Distribution B.V., Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. tolvaptan - EMEA/H/C/005961

treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. doxorubicin hydrochloride - EMEA/H/C/005330

treatment of breast cancer, treatment of ovarian cancer, treatment of multiple myeloma, treatment of AIDS related Kaposi's sarcoma

Scope: Letter by the applicant dated 31.03.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in March 2022.

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 28.05.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2022.

3.4.2. pegfilgrastim - EMEA/H/C/005810

Treatment of neutropenia

Scope: Letter by the applicant dated 07.04.2022 requesting an extension to the clock stop to respond to the list of questions adopted in January 2022.

Action: For adoption

List of Questions adopted on 27.01.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in January 2022.

3.4.3. artesunate - Orphan - EMEA/H/C/005718

B And O Pharm; Treatment of severe malaria

Scope: Letter by the applicant dated 06.04.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.09.2021, 22.07.2021. List of Questions adopted on 22.04.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

3.4.4. lenadogene nolparvovec - Orphan - ATMP - EMEA/H/C/005047

GenSight Biologics S.A.; treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)

Scope: Letter by the applicant dated 07.04.2022 requesting an extension to the clock stop to respond to the list of questions adopted in February 2021.

Action: For information

List of Questions adopted on 19.02.2021.

The CHMP noted the extension of clock stop as endorsed by the CAT.

3.4.5. spironolactone ph. eur. - EMEA/H/C/005535

Management of refractory oedema

Scope: Letter by the applicant dated 19.04.2022 requesting an extension to the clock stop to respond to the list of questions adopted in March 2022.

Action: For adoption

List of Questions adopted on 24.03.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2022.

3.4.6. autologous glioma tumour cells, inactivated / autologous glioma tumour cell lysates, inactivated / allogeneic glioma tumour cells, inactivated / allogeneic glioma tumour cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.), treatment of glioma

Scope: Update on oral explanation held at April CAT

Action: For information

List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

The Committee was informed about the oral explanation that took place at the April CAT meeting.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Aduhelm - aducanumab - EMEA/H/C/005558

Biogen Netherlands B.V., Alzheimer's disease

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

See 2.2

The CHMP noted the withdrawal of the re-examination request.

The question-and-answer document was circulated for information.

3.6. Initial applications in the decision-making phase

3.6.1. Yselty - linzagolix choline - EMEA/H/C/005442

ObsEva Ireland Ltd, for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids

Scope: Revised opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 24.02.2022. Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 11.11.2021, 16.09.2021. List of Questions adopted on 22.04.2021.

The Committee adopted a revised positive opinion by consensus, recommending the granting of a marketing authorisation by consensus together with the CHMP assessment

report.

The CHMP noted the letter of recommendations dated 22 April 2022.

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Neffy - epinephrine - EMEA/H/C/005584

ARS Pharmaceuticals IRL Limited; For the emergency treatment of allergic reactions, including anaphylaxis.

Scope: Withdrawal of marketing authorisation application

Action: For information

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 25.03.2021.

The CHMP noted the withdrawal of marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

No items

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Procysbi - mercaptamine - Orphan - EMEA/H/C/002465/X/0035

Chiesi Farmaceutici S.p.A.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form associated with two new strengths (75 and 300 mg gastro-resistant granules). The RMP (version 7.2) is updated in accordance."

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee discussed the issues identified in this application, concerning the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.2. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to add a new strength (45 mg) of the prolonged-release tablets, grouped with a type II variation (C.I.6.a) to include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent; as a consequence of the EoI, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 6.0) has also been submitted."

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G

Astellas Pharma Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Dupixent - dupilumab - EMEA/H/C/004390/X/0057

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus

Scope: quality

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to:
- introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (600 mg) and a new route of administration (intravenous use).
- add a new strength of 360 mg (150 mg/ml) for risankizumab solution for injection (in cartridge) for subcutaneous use.
The above new presentations are indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable. The RMP (version 4.0) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.4. Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 1 year and above). The paediatric indication is applicable to the new presentation (2 mg/ml granules for oral suspension) as well as all approved presentations (EU/1/20/1500/001 and 002). The RMP (version 2.0) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0074

GlaxoSmithkline Biologicals SA

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include use in children from 6 months to <18 years for Adjupanrix based on the results of the studies: study H5N1-013, a phase II, non-randomized, open-label study to evaluate the safety and immunogenicity in children aged 6 to 35 months and study H5N1-032, a phase III, randomized, open, active-controlled study to evaluate the safety and immunogenicity in children aged 3 to 17 years. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 6.6 of the SmPC are updated and the Package Leaflet is updated in accordance. Further, the MAH proposed to update section 4.4 with information on sodium and potassium content in line with the excipient guideline, as well as to add wording on traceability. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2, the MAH performed minor editorial changes and removed information related to the withdrawn Prepandrix marketing authorisation. Version 13 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.2. Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0002

BeiGene Ireland Ltd

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy, based on data from 88 patients with R/R MZL from 2 ongoing pivotal studies; study BGB-3111-214: A Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of zanubrutinib in patients with R/R MZL, and study BGB-3111-AU-003: A first-in-human, Phase 1/2, dose-escalation and selection, PK/pharmacodynamic, safety, and efficacy study in adult patients with R/R or treatment-naive B-cell malignancies. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH is requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Bydureon - exenatide - EMEA/H/C/002020/II/0073

AstraZeneca AB

Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include the treatment of adolescents and children aged 10 years and above based on the results from study BCB114 (D5551C00002); a phase 3, double-blind, placebo-controlled, randomized, multi-centre study to assess the safety and efficacy of exenatide once weekly in adolescents with type 2 diabetes, which was initially submitted and assessed by the CHMP as part of the post-authorisation measure (PAM) P46 028. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated and the Package Leaflet is updated in accordance. Version 35s1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.4. Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0061

Organon N.V.

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adolescent males (14 to less than 18 years) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG) for Elonva, based on final results of the paediatric study P043. Study P043 was an open-label, non-comparative, multi-center safety and efficacy study of corifollitropin in association with hCG in male adolescents with hypogonadotropic hypogonadism, part of the paediatric investigation plan; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.2 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement some minor editorial and formatting changes throughout the PI."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.5. Evrysdi - risdiplam - Orphan - EMEA/H/C/005145/II/0005/G

Roche Registration GmbH

Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Jan Neuhauser

Scope: "Grouping of three variations as follows:
Extension of indication to include treatment of patients below 2 months of age based on interim results from study BN40703 (RAINBOWFISH). The pivotal study RAINBOWFISH is an ongoing phase II multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability, and PK/PD of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with SMA. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to make some editorial improvements in the product information. A revised RMP version 1.1 was also submitted as part of the application.
Type IAIN, B.IV.1.a.1 variation to update Evrysdi pack configuration with the addition of a new 1 mL oral syringe into the product carton allowing precise dosing of infants below 2 months of age. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance.
Type IAIN, B.IV.1.b variation to remove the spare unit of 12 mL oral syringe out of the two units currently provided in the product carton. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. Fintepla - fenfluramine - Orphan - EMEA/H/C/003933/II/0012

Zogenix ROI Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of seizures associated with Lennox-Gastaut syndrome as an add on therapy to other anti-epileptic medicines for patients 2 years of age and older. As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. Imcivree - setmelanotide - Orphan - EMEA/H/C/005089/II/0002/G

Rhythm Pharmaceuticals Netherlands B.V.

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Marek Juracka

Scope: "Group of variations consisting of:
C.I.6.a - To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted.
C.I.6.a - To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Alström syndrome (AS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The CHMP noted the withdrawal of the Alström syndrome (AS) indication from the Type II variation.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.8. Imfinzi - durvalumab - EMEA/H/C/004771/II/0041

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, based on final results from study D419MC00004 (POSEIDON); This was a Phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy and safety of tremelimumab and durvalumab or durvalumab in combination with platinum based chemotherapy for first-line treatment in patients with metastatic NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2. Version 5.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0110

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery of adults with locally advanced, inflammatory, or early-stage triple-negative breast cancer at high-risk of recurrence; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 37.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022, 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.10. Libtayo - cemiplimab - EMEA/H/C/004844/II/0028

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include LIBTAYO in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations; as a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are

updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.11. Lynparza - olaparib - EMEA/H/C/003726/II/0051/G

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include adjuvant treatment of breast cancer for Lynparza (for tablets); as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. In addition, section 4.8 of the SmPC for Lynparza hard capsules is revised based on the updated safety data analysis. The Package Leaflet is updated in accordance. Version 23 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. Lynparza - olaparib - EMEA/H/C/003726/II/0053

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone, based on the results of the pivotal Phase III study PROpel (D081SC00001) and supportive evidence from study 8 (D081DC00008). PROpel is a Phase III, randomised, double-blind, placebo-controlled, multicentre study evaluating olaparib vs placebo in combination with abiraterone as first-line treatment for men with mCRPC. Consequently, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC for Lynparza tablets are being updated. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on the updated safety data analysis. The Package Leaflet is updated accordingly. The RMP version 24 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.13. Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update minor editorial and linguistic changes in the SmPC and Package Leaflet.
As part of the application, the MAH is also requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.14. NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0116

Novo Nordisk A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of severe postpartum haemorrhage for NovoSeven. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is also updated in accordance. Version 8.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.15. Olumiant - baricitinib - EMEA/H/C/004085/II/0029/G

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: "Grouping of the following variations:
C.I.6 - Extension of indication to include treatment of severe alopecia areata in adult

patients for Olumiant; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.1 of the RMP has also been submitted.
C.I.11.z - Update of RMP (version 12.1) to change the category 3 study PASS I4V-MC-B011 end of data collection for the Atopic Dermatitis cohort and the subsequent final study report milestone." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021.

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for 1 year of market protection.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.16. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0011

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the first-line treatment of RET fusion-positive NSCLC for Retsevmo based on results from study LIBRETTO-001, an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours; as a consequence, sections 4.1, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.17. Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0054/G

Shire Pharmaceuticals Ireland Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include patients from 4 months corrected gestational aged 1 year and above. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 are updated. The Package leaflet is updated accordingly.
Update of annex II to amend the date of completion of the post-authorisation study. The MAH took the opportunity to also amend local representatives."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.18. Revolade - eltrombopag - EMEA/H/C/001110/II/0068

Novartis Europharm Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) irrespective of time since initial diagnosis, based on an ad-hoc analysis of study TAPER (CETB115J2411); an ongoing phase II, open-label, prospective, single-arm study in adult ITP patients who are refractory or relapsed after first-line steroids.
As a consequence, sections 4.1 and 5.1 of the SmPC have been updated. In addition, the MAH took the opportunity to make some minor amendments in section 4.8 of the SmPC for increased consistency. An updated RMP version 54.0 has been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.19. Rinvoq - upadacitinib - EMEA/H/C/004760/II/0016

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation who have responded inadequately to NSAIDs or other conventional therapy, based on the final clinical study report from the pivotal study M19-944 study 2 (nr-axSpA); a randomized, double-blind, phase III study evaluating the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD in subjects with nr-axSpA who completed the double-blind period on study drug. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. A revised RMP version 8.0 was also submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.20. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0064

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "C.I.6 (Extension of indication)
Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC) for Tecentriq as monotherapy based on the results from the pivotal phase III study GO29527 (IMpower010); as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of both the Tecentriq 840 mg concentrate for solution for infusion SmPC and the Tecentriq 1,200 mg concentrate for solution for infusion SmPC are updated. Minor editorial changes have been made throughout the SmPC. The Package Leaflets are updated in accordance. Version 21.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022, 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.21. Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001

Merck Sharp & Dohme B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of infants, children and adolescents from 6 weeks to less than 18 years of age for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media for Vaxneuvance, based on final results from 1 Phase II study (V114-008) and 7 Phase III studies (V114-023, V114-024, V114-025, V114-027, V114-029, V114-030, V114-031); these are interventional studies to evaluate the safety, tolerability and immunogenicity of V114 in healthy and immunocompromised infants, children and adolescents. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include editorial changes in the product information. Version 1.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.22. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0042

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC, Annex II (section D) and the Package Leaflet are proposed to be updated. As a consequence, the RMP (version 5.1) has been updated to align with the indication extension.
In addition, the applicant has taken the opportunity to make minor editorial corrections throughout the SmPC and package leaflet to align with the current Quality Review of Documents (QRD) template." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 18.02.2022, 05.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.3.1. Tecfidera - dimethyl fumarate - EMEA/H/C/002601/II/0073

Biogen Netherlands B.V.

Re-examination Rapporteur: Daniela Philadelphy

Scope: "C.I.6 (Extension of indication) type II Art.29 Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatric patients from 10 years of age and over; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.3 are updated. The Package Leaflet is updated in accordance.
The MAH is requesting an extension of the market protection of one additional year in line with the guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in accordance with Article

14(11) of Regulation (EC) 726/2004.
Version 11.4 of the RMP has also been submitted to update the RMP (parts I-IV) based on study 109MS306 data supporting the request for a paediatric indication and the Applicant took the opportunity to update the RMP with the most updated data (Part II modules SIV, SV and SVII). " Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Scope: Opinion

Action: For adoption

Initial opinion adopted on 27.01.2022. Request for Supplementary Information adopted on 16.12.2021, 16.09.2021.

The scope of the re-examination procedure concerned the part of the initial opinion that did not recommend the requested extension of marketing protection in accordance with Article 14(11) of Regulation (EC) No 726/2004.

The Committee adopted a positive opinion by consensus, recommending the variation to the terms of the marketing authorisation concerning an extension of indication to include the treatment of relapsing remitting multiple sclerosis (RRMS) in paediatric patients from 13 years of age and over.

The CHMP discussed the request for 1 year of marketing protection for a new indication and considered by consensus that the new therapeutic indication brings a significant clinical benefit in comparison with existing therapies. However, having considered the judgement of 5 May 2021 in Case T 611/18, Pharmaceutical Works Polpharma v EMA, the CHMP concluded that the grant of 1 year of additional marketing authorisation for Tecfidera cannot be recommended at this time.

The summary of opinion was circulated for information.

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006078

detection of PD-L1 protein

Scope: Opinion

Action: For adoption

The Committee discussed the issues identified in this application, concerning the analytical performance.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

6.3.2. in vitro diagnostic medical device - EMEA/H/D/006065

In vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma

Scope: Opinion

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues, concerning the classification as companion diagnostic.

The Committee adopted a list of outstanding issues with a specific timetable.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 5 recommendations for eligibility to PRIME: 2 were accepted and 3 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Comirnaty - tozinameran - EMEA/H/C/005735/II/0104

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update immunogenicity, safety and efficacy information regarding heterologous vaccination (both in the primary series and for booster vaccinations) based on published literature data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.2. Spikevax - elasomeran - EMEA/H/C/005791/II/0057

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.3. Pregabalin Mylan Pharma – pregabalin – EMEA/H/C/003962

Mylan S.A.S; treatment of neuropathic pain, epilepsy and generalised anxiety disorder

(GAD)

Rapporteur: Alexandre Moreau

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

9.1.4. Xevudy - sotrovimab - EMEA/H/C/005676/II/0001/G

Glaxosmithkline Trading Services Limited

Rapporteur: Thalia Marie Estrup Blicher

Scope: "C.I.4 - Update of sections 4.4, 5.1 and 5.3 of the SmPC, to include new virology data based on the results from pharmacology studies, describing the conservation of the epitope as well as assessing any susceptibility changes due to either individual amino acid substitutions or emerging variants, including data against Omicron BA.1, BA.2 and BA.3; to include a warning to refer to the uncertainty of the clinical relevance of the observed decrease in "in vitro" neutralisation against Omicron BA.2, and include animal toxicology and pharmacology results observed from the cynomolgus monkey 2-week repeat-dose toxicology study. In addition, the MAH took the opportunity to implement editorial changes in sections 4.2, 4.8, 5.1, 5.2, 6.6 and 9 of the SmPC. The package leaflet is updated accordingly.
A.6 - To include the ATC Code J06BD05 in section 5.1 of the Summary of Product Characteristics (SmPC)."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.5. Imfinzi - durvalumab - EMEA/H/C/004771/II/0034

AstraZeneca AB

Rapporteur: Thalia Marie Estrup Blicher

Scope: "Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes. In addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 20.01.2022, 21.10.2021.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

9.1.6. Jardiance - empagliflozin - EMEA/H/C/002677/II/0062/G

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege

Scope: "Update of section 5.1 of the SmPC with the results of clinical study EMPULSE (1245-0204), a multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensated chronic HF) who have been StabilisEd (EMPULSE). In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 10.02.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.7. Rubraca - rucaparib - EMEA/H/C/004272/II/0029

Clovis Oncology Ireland Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022, 11.11.2021.

The Committee discussed the issues identified in this application.

The CHMP noted the notification from the European Commission (EC) initiating a procedure under Article 20 of Regulation (EC) No 726/2004 and requesting the Agency/CHMP to assess the benefit-risk balance of the centrally authorised medicinal product Rubraca (rucaparib) in the approved '3rd line or more treatment'.

See 10.1

9.1.8. Starlix – nateglinide – EMEA/H/C/000335

Novartis Europharm Limited; treatment of type 2 diabetes

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Alexandre Moreau

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

9.1.9. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052

AstraZeneca AB

Rapporteur: Sol Ruiz

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, RHH-001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.10. Libtayo - cemiplimab - EMEA/H/C/004844/R/0029

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst

Scope: Renewal of conditional marketing authorisation, proposal to switch from conditional to standard MA

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the risk-benefit balance remains favourable and that all specific obligations have been fulfilled, therefore the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations.

9.1.11. Elzonris - tagraxofusp – Orphan - EMEA/H/C/005031/II/0009

Stemline Therapeutics B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Submission of the final report from study 20255431 (CRL-263114) 'Characterisation of fixed choroid plexus samples from primate study MPI-2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The RMP version 2.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 13.01.2022.

The Committee discussed the issues identified in this application, concerning non-clinical study results and their possible impact on the clinical aspects and the RMP.

The CHMP adopted a request for PRAC advice.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.12. Natpar – parathyroid hormone – EMEA/H/C/003861

Takeda Pharmaceuticals International AG; treatment of hypoparathyroidism

Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Agnes Gyurasics

DHPC

Action: For information

The CHMP noted the DHPC and communication plan.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. Rubraca - rucaparib - EMEA/H/A-20/1518/C/4272/0033

Clovis Oncology Ireland Limited

Referral Rapporteur: Blanca Garcia-Ochoa, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Start of Art.20 referral; appointment of rapporteurs, LoQ, timetable

Opinion on temporary measures

Action: For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of the centrally authorised medicinal product Rubraca (rucaparib) in the approved '3rd line or more treatment'.
EMA has started a review of the cancer medicine Rubraca (rucaparib camsylate) when it is used to treat cancer of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after platinum-based chemotherapy and who can no longer have these medicines.
The review follows preliminary results indicating that overall survival was shorter in these patients than in those receiving chemotherapy. These results come from the ongoing ARIEL4 study1 comparing Rubraca with chemotherapy in patients with high-grade cancer of the ovary, fallopian tubes or peritoneum with a BRCA mutation whose cancer has come back after chemotherapy.

CHMP appointed Blanca Garcia-Ochoa as referral rapporteur and Paula Boudewina van Hennik as referral co-rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Notification: 22 April 2022

Start of the procedure (CHMP): April 2022 CHMP

List of questions: 22 April 2022

Submission of responses: 05 May 2022

Re-start of the procedure: 26 May 2022

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 03 June 2022

Comments: 10 June 2022

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 16 June 2022

CHMP list of outstanding issues/CHMP opinion: June 2022 CHMP

The CHMP also adopted an opinion on temporary measures by consensus, recommending that as a precaution, while the review in ongoing, not to start new monotherapy treatment with rucaparib for adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. Therefore, the CHMP was of the opinion that the recommended the terms of the marketing authorisation for Rubraca (rucaparib) should be varied. The CHMP adopted the assessment report on temporary measures.

This opinion is without prejudice to the final conclusions of the ongoing procedure under Article 20 of Regulation (EC) No 726/2004.

This recommendation does not affect the use of Rubraca as maintenance treatment following chemotherapy. The CHMP agreed to the DHPC and communication plan to inform Healthcare professionals in writing of the updated treatment recommendations.

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Daruph and Anafezyn - dasatinib (anhydrous) - EMEA/H/A-29(4)/1516

Zentiva k.s.

Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani

Scope: List of outstanding issues

Action: For adoption

Decentralised Procedure number: SE/H/2098/01–06/DC; SE/H/2099/01–06/DC, notification by the Swedish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MSs are of the opinion that a positive benefit risk balance is not established under Article 10(3) of Directive 2001/83/EC, as applied, in the absence of bioequivalence and that additional justification is needed to support extrapolation of efficacy and safety to the reference product. Concerns are also raised on the different warning with the reference medicinal product regarding concomitant administration of PPI and /or H2-antagonist and the risk of medication error.

The Committee adopted a list of outstanding issues with a specific timetable.

CHMP list of outstanding issues: April 2022 CHMP

Submission of responses: 27 April 2022

Re-start of the procedure: 02 May 2022

Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 06 May 2022

Comments: 11 May 2022

Updated Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 13 May 2022

CHMP opinion: May 2022 CHMP

The CHMP agreed to consult the PKWP and adopted a list of questions to the group of experts.

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

April 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for April 2022

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at April 2022 PDCO

Action: For information

The CHMP noted the information.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Sean Barry

Reports from BWP April 2022 meeting to CHMP for adoption:

- 16 reports on products in scientific advice and protocol assistance
- 13 reports on products in pre-authorisation procedures
- 1 report on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Joint QWP/BWP Launch call for nominations to Quality Innovation Group

Joint QWP/BWP request.

In the context of the new operational model of working parties and Operational Expert Group (OEGs) that was agreed at the EMA Management Board in April 2021, this is a request to launch the call for nominations for the Quality Innovation Group. Nominations

should be sent by 27 May 2022.

Follow-up on the April 2022 PROM.

Action: For adoption

The CHMP endorsed the call for nominations.

14.3.3. Revision of the EU pharmaceutical legislation

Follow-up on new Pharmaceutical Strategy

Action: For information

The CHMP noted the update.

14.3.4. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 04-07 April 2022. Table of conclusions

Action: For information

The CHMP noted the information.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.5. Election of Scientific Advice Working Party vice-chair

Election of SAWP vice-chair. The second mandate of Scientific Advice Working Party vice-chair Peter Mol will expire in May 2022.

Action: For adoption

Nomination(s) received

The CHMP elected Pierre Demolis as SAWP vice-chair.

14.3.6. Chair and Vice-Chair election of Working Parties

Election of chair and vice-chair of the following working parties:

- Central Nervous System WP
- Cardiovascular WP
- Rheumatology and Immunology WP
- Vaccine WP
- Infectious Diseases WP
- Haematology WP
- Methodology WP
- Oncology WP
- Non-clinical WP

Action: For adoption

The CHMP elected Andre Elferink as chair of the Central Nervous System Working Party, Alar Irs as chair of the Cardiovascular Working Party, Romaldas Maciulaitis as chair of the Rheumatology and Immunology Working Party, Mair Powell as chair of the Vaccine Working Party, Christian roes as chair and Kristin Karlsson as vice-chair of the Methodology Working Party, Pierre Demolis as chair and Sigrid Klaar as vice-chair of the Oncology Working Party, Susanne Brendler-Schwaab as chair and Karen van Malderen as vice-chair of the Non-Clinical Working Party.

The CHMP noted the call for nomination for the remaining positions.

14.3.7. Rheumatology and Immunology Working Party

Call for an additional member with expertise in the respiratory field

Action: For information

The CHMP noted the call and agreed to continue with the election of chair and vice-chair before appointment of an additional member.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the information.

15.1.2. COVID-19 vaccine (inactivated, adjuvanted, adsorbed) - EMEA/H/C/006019

prevention of coronavirus disease-2019 (COVID-19)

Scope: Rolling review 2nd interim opinion

Action: For adoption

The CHMP adopted the rolling review 2nd interim opinion.

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 19–22 April 2022 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Bruno Sepodes	Member (Vice-Chair, deputising for the Chair)	Portugal	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Aaron Sosa Mejia	Alternate	Denmark	No participation in final deliberations and voting on	Actrapid - insulin human - Article 58 - EMEA/H/W/005779 Insulatard - insulin human - Article 58 - EMEA/H/W/005780 NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0116
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jan Sjöberg	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Carola de Beaufort	Alternate	Luxembourg	No restrictions applicable to this meeting	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Jörg Engelbergs	Expert - via WebEx*	Germany	No interests declared	
Sargi Caizergues Lama	Expert - via WebEx*	France	No interests declared	
Stephanie Hueber	Expert - via WebEx*	France	No interests declared	
Céline Jumeau	Expert - via WebEx*	France	No interests declared	
Roxane Fornacciari	Expert - via WebEx*	France	No interests declared	
Naissant Gwladys	Expert - via WebEx*	France	No interests declared	
Fabien Carré	Expert - via WebEx*	France	No interests declared	
Caroline de Oliveira	Expert - via WebEx*	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Vincent Gazin	Expert - via WebEx*	France	No interests declared	
Anissa Benlazar	Expert - via WebEx*	France	No interests declared	
Wiem Abid	Expert - via WebEx*	France	No interests declared	
Lars Peter Engeset Austdal	Expert - via WebEx*	Norway	No interests declared	
David Olsen	Expert - via WebEx*	Norway	No restrictions applicable to this meeting	
Harald Bernsteiner	Expert - via WebEx*	Austria	No interests declared	
Franz Rieder-Rommer	Expert - via WebEx*	Austria	No interests declared	
Karl Katholnig	Expert - via WebEx*	Austria	No restrictions applicable to this meeting	
Elisabeth Wischnitzki	Expert - via WebEx*	Austria	No interests declared	
Edwige Haelterman Brenneisen	Expert - via WebEx*	Belgium	No interests declared	
Inne Crèvecoeur	Expert - via WebEx*	Belgium	No participation in discussion, final deliberations and voting on	Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001
Olga Kholmanskikh	Expert - via WebEx*	Belgium	No interests declared	
Tim Leest	Expert - via WebEx*	Belgium	No interests declared	
Miranda Vroenhove	Expert - via WebEx*	Belgium	No interests declared	
Stefan Bonné	Expert - via WebEx*	Belgium	No interests declared	
Valerie Lescrainier	Expert - via WebEx*	Belgium	No interests declared	
Mario Miguel Coelho da Silva Rosa	Expert - via WebEx*	Portugal	No interests declared	
Kairi Rooma	Expert - via WebEx*	Estonia	No interests declared	
Eeva Sofia Leinonen	Expert - via WebEx*	Finland	No interests declared	
Maija Tarkkanen	Expert - via WebEx*	Finland	No interests declared	
Elina Asikanius	Expert - via WebEx*	Finland	No restrictions applicable to this meeting	
Mair Powell	Expert - via WebEx*	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Finbarr Leacy	Expert - via WebEx*	Ireland	No interests declared	
Iftekhar Khan	Expert - via WebEx*	Ireland	No interests declared	
Peter Twomey	Expert - via WebEx*	Ireland	No restrictions applicable to this meeting	
Norah Cassidy	Expert - via WebEx*	Ireland	No restrictions applicable to this meeting	
Jeanette McCallion	Expert - via WebEx*	Ireland	No interests declared	
Anne-Marie Dalseg	Expert - via WebEx*	Denmark	No interests declared	
Kristina Skougaard	Expert - via WebEx*	Denmark	No interests declared	
Meera Varma	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Kristina Bech Jensen	Expert - via WebEx*	Denmark	No interests declared	
Nanna Borup Johansen	Expert - via WebEx*	Denmark	No interests declared	
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Emilie Birch Kristensen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Mette Linnert Jensen	Expert - via WebEx*	Denmark	No interests declared	
Doris Johanna Hovgaard	Expert - via WebEx*	Denmark	No interests declared	
Line Praest Lauridsen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Anne Hasle Buur	Expert - via WebEx*	Denmark	No interests declared	
Ebru Karakoc Madsen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No participation in discussion, final deliberations and voting on	Rinvoq - upadacitinib - X/0012/G II/0016 Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G
Maria Victoria Tudanca Pacios	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Mas Parra Paloma	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Carolina Prieto Fernandez	Expert - via WebEx*	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Lucia Lopez-Anglada Fernandez	Expert - via WebEx*	Spain	No interests declared	
Macarena Gajardo	Expert - via WebEx*	Spain	No interests declared	
Luisa Valer	Expert - via WebEx*	Spain	No interests declared	
Lourdes Rodriguez Rojas	Expert - via WebEx*	Spain	No interests declared	
Cristina Lucía Rueda Pérez	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Agustin Portela Moreira	Expert - via WebEx*	Spain	No interests declared	
Alicia Pérez González	Expert - via WebEx*	Spain	No interests declared	
Ana Sagredo	Expert - via WebEx*	Spain	No interests declared	
Macarena Rodriguez Mendizabal	Expert - via WebEx*	Spain	No interests declared	
Paolo Foggi	Expert - via WebEx*	Italy	No interests declared	
Rune Kjeken	Expert - via WebEx*	Norway	No restrictions applicable to this meeting	
Larissa Higgins	Expert - via WebEx*	Ireland	No interests declared	
Serena Marchetti	Expert - via WebEx*	Netherlands	No interests declared	
Adriana Andrić	Expert - via WebEx*	Hungary	No interests declared	
Pierre Demolis	Expert - via WebEx*	France	No interests declared	
Livia Puljak	Expert - via WebEx*	Hungary	No interests declared	
Andreas Kirisits	Expert - via WebEx*	Austria	No interests declared	
Joerg Zinserling	Expert - via WebEx*	Germany	No interests declared	
Mogens Westergaard	Expert - via WebEx*	Denmark	No interests declared	
Charlotte Anderberg	Expert - via WebEx*	Sweden	No restrictions applicable to this meeting	
Diana Vasilcanu	Expert - via WebEx*	Sweden	No interests declared	
Kourosh Lotfi	Expert - via WebEx*	Sweden	No interests declared	
An Na Joo	Expert - via WebEx*	Sweden	No restrictions applicable to this meeting	
Uta Buckpesch-Heberer	Expert - via WebEx*	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Hilke Zander	Expert - via WebEx*	Germany	No interests declared	
Susanne Mueller-Egert	Expert - via WebEx*	Germany	No interests declared	
Yasmin Molter	Expert - via WebEx*	Germany	No interests declared	
Greger Abrahamsen	Expert - via WebEx*	Norway	No interests declared	
Venke Skibeli	Expert - via WebEx*	Norway	No interests declared	
Therese Solstad Saunders	Expert - via WebEx*	Norway	No interests declared	
André Elferink	Expert - via WebEx*	Netherlands	No interests declared	
Pierre Demolis	Expert - via WebEx*	France	No interests declared	
Susanne Brendler-Schwaab	Expert - via WebEx*	Germany	No interests declared	
Günter Waxenecker	Expert - via WebEx*	Austria	No restrictions applicable to this meeting	
Sean Barry	Expert - via WebEx*	Ireland	No restrictions applicable to this meeting	
Roeland Martijn Van der Plas	Expert - via WebEx*	Netherlands	No interests declared	
Barbora Ladinova	Expert - via WebEx*	Czechia	No interests declared	
Pavel Simek	Expert - via WebEx*	Czechia	No interests declared	
Katerina Pospisilova	Expert - via WebEx*	Czechia	No interests declared	
Ingrid Schellens	Expert - via WebEx*	Netherlands	No interests declared	
Saskia Bergervoet	Expert - via WebEx*	Netherlands	No interests declared	
Hannelore Samyn	Expert - via WebEx*	Netherlands	No interests declared	
Michel Kooijman	Expert - via WebEx*	Netherlands	No interests declared	
Katrien Oude Rengerink	Expert - via WebEx*	Netherlands	No participation in discussion, final deliberations and voting on	molnupiravir - EMEA/H/C/005789 Keytruda - pembrolizumab - EMEA/H/C/003820/II/0110 Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001
Hester Peltenburg	Expert - via WebEx*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jaap Fransen	Expert - via WebEx*	Netherlands	No interests declared	
Nafise Ghalandari	Expert - via WebEx*	Netherlands	No interests declared	
Johannes Petrus Theodorus Span	Expert - via WebEx*	Netherlands	No interests declared	
Steven Teerenstra	Expert - via WebEx*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via WebEx*	Netherlands	No interests declared	
Emmely de Vries	Expert - via WebEx*	Netherlands	No interests declared	
Stavros Nikolakopoulos	Expert - via WebEx*	Netherlands	No interests declared	
Jennifer ten Kulve	Expert - via WebEx*	Netherlands	No interests declared	
Taco Monster	Expert - via WebEx*	Netherlands	No interests declared	
Patrick Vrijlandt	Expert - via WebEx*	Netherlands	No interests declared	
Jana Schweigertova	Expert - via WebEx*	Slovakia	No interests declared	
Elsa Grangier	Expert - via WebEx*	France	No interests declared	
Martin Huber	Expert - via WebEx*	Germany	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	
Luca Santi	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert - via WebEx*	Italy	No participation in discussion, final deliberations and voting on	Procysbi - mercaptamine - Orphan - EMEA/H/C/002465/X/0035
Cristina Migali	Expert - via WebEx*	Italy	No interests declared	
Camilla Festa	Expert - via WebEx*	Italy	No interests declared	
Floriana D'Urso	Expert - via WebEx*	Italy	No interests declared	
Alessia Proietti	Expert - via WebEx*	Italy	No interests declared	
Maria Di Marzo	Expert - via WebEx*	Italy	No interests declared	
Antonella Isgrò	Expert - via WebEx*	Italy	No interests declared	
Marco Di Girolamo	Expert - via WebEx*	Italy	No interests declared	
Laura Galatti	Expert - via WebEx*	Italy	No interests declared	
Sara Galluzzo	Expert - via WebEx*	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Angelo Molinaro	Expert - via WebEx*	Italy	No interests declared	
Valeria Di Muzio	Expert - via WebEx*	Italy	No interests declared	
Simona Teodosiu	Expert - via WebEx*	France	No interests declared	
Kristin Karlsson	Expert - via WebEx*	Sweden	No interests declared	
Helena Back	Expert - via WebEx*	Sweden	No interests declared	
Anders Lignell	Expert - via WebEx*	Sweden	No interests declared	
Sabrina Tripolt	Expert - via WebEx*	Austria	No interests declared	
Johanna Wernsperger	Expert - via WebEx*	Austria	No interests declared	
Birger Scholz	Expert - via WebEx*	Sweden	No interests declared	
Tania Meier	Expert - via WebEx*	Germany	No interests declared	
Sarah Gilgunn	Expert - via WebEx*	Ireland	No interests declared	
Christian Roes	Expert - via WebEx*	Netherlands	No participation in discussion, final deliberations and voting on	Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0061
Sabine Mayrhofer	Expert - via WebEx*	Germany	No interests declared	
Irene Bachmann	Expert - via WebEx*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via WebEx*	Germany	No interests declared	
Marion Haberkamp	Expert - via WebEx*	Germany	No interests declared	
Susanne Steinecker	Expert - via WebEx*	Germany	No interests declared	
George Aislaitner	Expert - via WebEx*	Germany	No interests declared	
Ana Vitez	Expert - via WebEx*	Croatia	No interests declared	
Marija Pekas	Expert - via WebEx*	Croatia	No interests declared	
Marina Lesičar	Expert - via WebEx*	Croatia	No interests declared	
Karen Van Malderen	Expert - via WebEx*	Belgium	No interests declared	
Evelyn Soo	Expert - via WebEx*	Health Canada	No interests declared	
Mohit Khera	Expert - via WebEx*	TGA Australia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Nitin Bagul	Expert - via WebEx*	TGA Australia	No interests declared	
Deepak Rai	Expert - via WebEx*	TGA Australia	No interests declared	
Serge Bakchine	Expert - via phone*	France	No interests declared	
Manuel Schiff	Expert - via phone*	France	No restrictions applicable to this meeting	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Medical devices *(Section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on an ancillary medicinal substance in a medical device or on the suitability of a companion diagnostic in relation to the medicinal product(s) concerned.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 June 2022
EMA/CHMP/223814/2022

Annex to 19-22 April 2022 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000
An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for April 2022: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for April 2022: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Defitelio - defibrotide - EMEA/H/C/002393/S/0057, Orphan Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 24.02.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
ELZONRIS - tagraxofusp - EMEA/H/C/005031/S/0012, Orphan Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
Obizur - susoctocog alfa - EMEA/H/C/002792/S/0044 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski Request for Supplementary Information adopted on 24.02.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
SCENESSE - afamelanotide - EMEA/H/C/002548/S/0041, Orphan Clinuvel Europe Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Cuprymina - copper (64Cu) chloride - EMEA/H/C/002136/R/0023 A.C.O.M. - Advanced Center Oncology Macerata - S.R.L., Rapporteur: Armando Genazzani, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Ilaria Baldelli	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Dupixent - dupilumab - EMEA/H/C/004390/R/0053 sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola Request for Supplementary Information adopted on 22.04.2022, 27.01.2022.	Request for supplementary information adopted with a specific timetable.
Entecavir Accord - entecavir - EMEA/H/C/004458/R/0011 Accord Healthcare S.L.U., Generic, Generic of Baraclude, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Entecavir Mylan - entecavir - EMEA/H/C/004377/R/0008 Mylan Pharmaceuticals Limited, Generic, Generic of Baraclude, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Lacosamide Accord - lacosamide - EMEA/H/C/004443/R/0015 Accord Healthcare S.L.U., Generic, Generic of Vimpat, Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Nitisinone MDK - nitisinone - EMEA/H/C/004281/R/0013	Positive Opinion adopted by consensus together with the CHMP assessment report and

MendeliKABS Europe Limited, Generic, Generic of Orfadin, Rapporteur: Alar Irs, PRAC Rapporteur: Ilaria Baldelli	translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Xermelo - telotristat ethyl - EMEA/H/C/003937/R/0032, Orphan Ipsen Pharma, Rapporteur: Martina Weise, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 24.02.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/R/0014, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, Co-Rapporteur: Heli Suila, CHMP Coordinators: Ingrid Wang and Johanna Lähteenvuo, PRAC Rapporteur: Annika Folin	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0010, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Johanna Lähteenvuo, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Dovprela - pretomanid - EMEA/H/C/005167/R/0010, Orphan Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Hepcludex - bulevirtide - EMEA/H/C/004854/R/0013, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, PRAC Rapporteur:	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal

Adam Przybylkowski	for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Idefirix - imlifidase - EMEA/H/C/004849/R/0007, Orphan Hansa Biopharma AB, Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
LIBTAYO - cemiplimab - EMEA/H/C/004844/R/0029 Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 24.03.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the risk-benefit balance remains favourable and that all specific obligations have been fulfilled, therefore the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations. See 9.1
Translarna - ataluren - EMEA/H/C/002720/R/0067, Orphan PTC Therapeutics International Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its April 2022 meeting:	
EMEA/H/C/PSUSA/00000432/202108 (brinzolamide) CAPS: **Azopt** (EMEA/H/C/000267) (brinzolamide), Novartis Europharm Limited, Rapporteur: Maria Concepcion Prieto Yerro NAPS: **NAPS** - NOVARTIS EUROPHARM LIMITED	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred

PRAC Rapporteur: Eva A. Segovia, "01/09/2016 To: 31/08/2021"	active substance(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the ADR SJS/TEN with a frequency 'not known' and a warning on SJS/TEN. The Package leaflet should be updated accordingly.
EMEA/H/C/PSUSA/00001816/202108 (lacosamide) CAPS: **Lacosamide UCB** (EMEA/H/C/005243) (lacosamide), UCB Pharma S.A., Rapporteur: Filip Josephson **Vimpat** (EMEA/H/C/000863) (lacosamide), UCB Pharma S.A., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "01/09/2018 To: 31/08/2021 Information."	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal products, concerning the following change(s): Update of section 4.6 of the SmPC to add information that lacosamide is excreted in breast milk. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00001988/202109 (mercaptopurine) CAPS: **Xaluprine** (EMEA/H/C/002022) (mercaptopurine), Nova Laboratories Ireland Limited, Rapporteur: Filip Josephson NAPS: **NAP** - EU PRAC Rapporteur: Annika Folin, "02/09/2016 To: 01/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction erythema nodosum with a frequency Unknown. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010042/202108 (crizotinib) CAPS: **XALKORI** (EMEA/H/C/002489) (crizotinib), Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "26/08/2019 To: 25/08/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Updates of sections 4.4 and 4.8 of the SmPC to add the adverse reaction "photosensitivity" with a frequency "uncommon" (<1%) based on the frequency observed in clinical studies. The package leaflet is updated accordingly and to add the adverse reaction "Blood creatine phosphokinase increased" with a frequency "Uncommon" (<1%). The package leaflet is amended accordingly.

EMEA/H/C/PSUSA/00010055/202109 (alemtuzumab) CAPS: **Lemtrada** (EMEA/H/C/003718) (alemtuzumab), Sanofi Belgium, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, "12/09/2020 To: 12/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product, concerning the following change: Update of section 4.4 of the SmPC to add a warning on autoimmune encephalitis and 4.8 to add the adverse reaction autoimmune encephalitis with a frequency uncommon.
EMEA/H/C/PSUSA/00010366/202109 (naltrexone / bupropion) CAPS: **Mysimba** (EMEA/H/C/003687) (naltrexone hydrochloride / bupropion hydrochloride), Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "09/09/2020 To: 09/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to amend the existing warning on neuropsychiatric symptoms and section 4.8 of the SmPC to add the adverse reaction panic attack with a frequency not known. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010403/202109 (pembrolizumab) CAPS: **Keytruda** (EMEA/H/C/003820) (pembrolizumab), Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, "03/09/2020 To: 03/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 2 of the package leaflet to add the risk of diabetic ketoacidosis, including the symptoms.
EMEA/H/C/PSUSA/00010426/202109 (isavuconazole) CAPS: **Cresemba** (EMEA/H/C/002734) (isavuconazole), Basilea Pharmaceutica Deutschland GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, "06/09/2020 To: 06/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product, concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction anaphylactic reaction with a frequency not known and a warning on anaphylactic reaction. The Package leaflet is

	updated accordingly.
EMEA/H/C/PSUSA/00010720/202109 (tildrakizumab) CAPS: **Ilumetri** (EMEA/H/C/004514) (tildrakizumab), Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski, "20/03/2021 To: 19/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to amend immunogenicity wording. Update of the package leaflet is not required.
EMEA/H/C/PSUSA/00010900/202109 (cabotegravir) CAPS: **Vocabria** (EMEA/H/C/004976) (cabotegravir), ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "17/03/2021 To: 17/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reactions "Type I hypersensitivity" and "urticaria, angioedema". Furthermore, as a general warning on hypersensitivity reactions in association with other integrase inhibitors is already included in section 4.4, only a small update of this section is necessary. The Package leaflet is updated accordingly.

B.4. EPARs / WPARs

Amifampridine SERB - amifampridine - EMEA/H/C/005839 SERB SA, treatment of Lambert-Eaton Myasthenic Syndrome, Generic, Generic of Firdapse, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Camcevi - leuprorelin - EMEA/H/C/005034 Accord Healthcare S.L.U., indicated for the treatment of hormone dependent advanced prostate cancer, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
CARVYKTI - ciltacabtagene autoleucel - EMEA/H/C/005095, Orphan, ATMP Janssen-Cilag International NV, treatment of multiple myeloma, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
EVUSHELD - tixagevimab / cilgavimab -	For information only. Comments can be sent to

EMEA/H/C/005788 AstraZeneca AB, pre-exposure prophylaxis of COVID-19 in adults 18 years of age and older, New active substance (Article 8(3) of Directive No 2001/83/EC)	the PL in case necessary.
Neffy (WD) - epinephrine - EMEA/H/C/005584 Ars Pharmaceuticals Irl Limited, emergency treatment of allergic reactions, including anaphylaxis, Known active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Zolsketil pegylated liposomal - doxorubicin - EMEA/H/C/005320 Accord Healthcare S.L.U., treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0045, Orphan Amgen Europe B.V., Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Cinacalcet Mylan - cinacalcet - EMEA/H/C/004014/II/0016 Mylan Pharmaceuticals Limited, Generic, Generic of Mimpara, Rapporteur: Tomas Radimersky Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 16.12.2021, 23.09.2021.	Positive Opinion adopted by consensus on 22.04.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0116/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0120/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Drovelis - drospirenone / estetrol - EMEA/H/C/005336/II/0006/G Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
Dupixent - dupilumab - EMEA/H/C/004390/II/0059/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Elaprase - idursulfase - EMEA/H/C/000700/II/0098/G Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Fluenz Tetra - influenza vaccine (live attenuated, nasal) - EMEA/H/C/002617/II/0113/G AstraZeneca AB, Rapporteur: Christophe Focke Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
GONAL-f - follitropin alfa - EMEA/H/C/000071/II/0154/G Merck Europe B.V., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
HEPLISAV B - hepatitis B surface antigen - EMEA/H/C/005063/II/0010 Dynavax GmbH, Rapporteur: Filip Josephson Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 14.10.2021.	Positive Opinion adopted by consensus on 07.04.2022.
Infanrix hexa - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/000296/II/0309/G GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke	Positive Opinion adopted by consensus on 07.04.2022.

Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 13.01.2022.	
JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0041/G Janssen-Cilag International N.V., Rapporteur: Christophe Focke Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0019/G Bayer AG, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 10.02.2022, 07.10.2021.	Positive Opinion adopted by consensus on 22.04.2022.
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0023 Bayer AG, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0036/G, Orphan Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Lydisilka - drospirenone / estetrol - EMEA/H/C/005382/II/0006/G Estetra SRL, Duplicate, Duplicate of Drovelis, Rapporteur: Kristina Dunder Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
MabThera - rituximab - EMEA/H/C/000165/II/0189/G Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Mekinist - trametinib - EMEA/H/C/002643/II/0053/G Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Memantine Mylan - memantine / memantine hydrochloride - EMEA/H/C/002660/II/0018	Positive Opinion adopted by consensus on 22.04.2022.

Mylan Pharmaceuticals Limited, Generic, Generic of Ebixa, Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 20.01.2022.	
MenQuadfi - meningococcal group a, c, w135 and y conjugate vaccine - EMEA/H/C/005084/II/0016/G Sanofi Pasteur, Rapporteur: Andrea Laslop Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Menveo - meningococcal group a, c, w135 and y conjugate vaccine - EMEA/H/C/001095/II/0106/G GSK Vaccines S.r.l, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Mycamine - micafungin - EMEA/H/C/000734/II/0044/G Astellas Pharma Europe B.V., Rapporteur: Janet Koenig Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 09.12.2021.	Positive Opinion adopted by consensus on 07.04.2022.
Nityr - nitisinone - EMEA/H/C/004582/II/0011 Cycle Pharmaceuticals (Europe) Limited, Generic, Generic of Orfadin, Rapporteur: Peter Kiely Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Nucala - mepolizumab - EMEA/H/C/003860/II/0049 GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0007 Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Ogivri - trastuzumab - EMEA/H/C/004916/II/0040 Viatris Limited, Rapporteur: Karin Janssen van	Positive Opinion adopted by consensus on 07.04.2022.

Doorn Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 17.02.2022.	
Pandemic influenza vaccine H5N1 AstraZeneca - pandemic influenza vaccine (H5N1) (live attenuated, nasal) - EMEA/H/C/003963/II/0048/G AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0001/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 17.03.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0003/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 17.03.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Revestive - teduglutide - EMEA/H/C/002345/II/0055, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 17.02.2022, 16.12.2021.	Positive Opinion adopted by consensus on 07.04.2022.
RoActemra - tocilizumab - EMEA/H/C/000955/II/0108 Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) -	Positive Opinion adopted by consensus on 22.04.2022.

EMEA/H/C/004336/II/0052/G GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke Opinion adopted on 22.04.2022.	
Soliris - eculizumab - EMEA/H/C/000791/II/0121, Orphan Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Synflorix - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/000973/II/0171/G GlaxoSmithkline Biologicals SA, Rapporteur: Kristina Dunder Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Tigecycline Accord - tigecycline - EMEA/H/C/005114/II/0002/G Accord Healthcare S.L.U., Generic, Generic of Tygacil, Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 31.03.2022, 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0062 AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 24.03.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0064/G AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0019/G Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 16.12.2021, 02.09.2021.	Positive Opinion adopted by consensus on 07.04.2022.
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0028/G, Orphan Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 07.04.2022.	
Wegovy - semaglutide - EMEA/H/C/005422/II/0001/G Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 31.03.2022.	Request for supplementary information adopted with a specific timetable.
Zinplava - bezlotoxumab - EMEA/H/C/004136/II/0031 Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
WS2138/G **Hexacima-EMEA/H/C/002702/WS2138/0120/G** **Hexyon-EMEA/H/C/002796/WS2138/0124/G** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 22.04.2022, 02.12.2021.	Request for supplementary information adopted with a specific timetable.
WS2159/G **Prolia-EMEA/H/C/001120/WS2159/0095/G** **XGEVA-EMEA/H/C/002173/WS2159/0079/G** Amgen Europe B.V., Lead Rapporteur: Kristina Dunder Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 17.03.2022.	Positive Opinion adopted by consensus on 22.04.2022.
WS2190 **Lixiana-EMEA/H/C/002629/WS2190/0036** **Roteas-EMEA/H/C/004339/WS2190/0023** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 17.02.2022.	Positive Opinion adopted by consensus on 22.04.2022.
WS2193 **Cancidas-EMEA/H/C/000379/WS2193/0075** **Cubicin-EMEA/H/C/000637/WS2193/0081** **Invanz-EMEA/H/C/000389/WS2193/0065** **Ivemend-EMEA/H/C/000743/WS2193/0046**	Request for supplementary information adopted with a specific timetable.

Noxafil-EMEA/H/C/000610/WS2193/0069 **PREVYMIS-** **EMEA/H/C/004536/WS2193/0025** **Recarbrio-** **EMEA/H/C/004808/WS2193/0013** **Sivextro-** **EMEA/H/C/002846/WS2193/0044** **Temodal-** **EMEA/H/C/000229/WS2193/0096** **Zerbaxa-** **EMEA/H/C/003772/WS2193/0037** Merck Sharp & Dohme B.V., Lead Rapporteur: Filip Josephson Request for Supplementary Information adopted on 31.03.2022.	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adempas - riociguat - EMEA/H/C/002737/II/0035, Orphan Bayer AG, Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study REPLACE (#18588/PH-41313). This is a prospective, randomized, international, multicenter, double-arm, controlled, open-label phase 4 study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal." Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Adtralza - tralokinumab - EMEA/H/C/005255/II/0001 LEO Pharma A/S, Rapporteur: Jayne Crowe, "C.I.4 Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with cytochrome P450 and CYP substrates based on final results from study ECZTRA 4 (LP0162-1342). This is an open-label drug–drug interaction trial to investigate the effects of tralokinumab on the pharmacokinetics of selected CYP substrates in adult subjects with moderate-to-severe atopic dermatitis. In addition, the MAH took the opportunity to make editorial changes to sections 4.8, 6.5 and 9 of SmPC." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 22.04.2022, 16.12.2021.	
Braftovi - encorafenib - EMEA/H/C/004580/II/0026 Pierre Fabre Medicament, Rapporteur: Janet Koenig, "Update of section 4.2 of the SmPC in order to introduce a new scheme of encorafenib dose reduction recommendations for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, by replacing the second dose reduction level of 200 mg once daily by 225 mg once daily; based on results from simulation report (ARRA-CSC-104). In addition, the MAH took the opportunity to introduce an update of the user instructions in the Package Leaflet for increased clarity." Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Caprelsa - vandetanib - EMEA/H/C/002315/II/0052 Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 4.4 of the SmPC in order to amend an existing warning on renal failure based on the safety signal evaluation report. In addition, the MAH took the opportunity to update the contact details for the local representative in DE in the Package Leaflet." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 24.02.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Cibinqo - abrocitinib - EMEA/H/C/005452/II/0002 Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, "Update of section 4.5 of the SmPC based on results from Drug-Drug Interaction (DDI) study B7451061; A phase 1, randomized, crossover study to evaluate relative Bioavailability of abrocitinib Oral suspension and effect of an Acid-reducing agent on the Bioavailability of abrocitinib Commercial tablet and to assess the taste of abrocitinib oral Formulations in healthy adult Participants aged 18 to 55 years of age." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Cometriq - cabozantinib - EMEA/H/C/002640/II/0049, Orphan	Positive Opinion adopted by consensus on 31.03.2022.

Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on hypertension and add hypertensive crisis to the list of adverse drug reactions (ADRs) with frequency not known based on literature review and post-marketing and clinical data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Opinion adopted on 31.03.2022. Request for Supplementary Information adopted on 03.02.2022.	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0104 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update immunogenicity, safety and efficacy information regarding heterologous vaccination (both in the primary series and for booster vaccinations) based on published literature data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 24.02.2022.	Positive Opinion adopted by consensus on 22.04.2022. See 9.1
Cosentyx - secukinumab - EMEA/H/C/003729/II/0084 Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, "Update of section 4.8 of the SmPC in order to add the new ADR "dyshidrotic eczema" with the frequency Uncommon based on post-marketing data. The section 4 of the Package Leaflet is updated accordingly." Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
Cotellic - cobimetinib - EMEA/H/C/003960/II/0025 Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study GO29665 (iMATRIX_cobimetinib) which corresponds to study 4 of PIP EMEA-C-001425-PIP01-13-M05. This is a phase I/II, multicentre, open-label, dose-escalation study of the safety, efficacy and pharmacokinetics of cobimetinib in	Request for supplementary information adopted with a specific timetable.

paediatric and young adult patients with previously treated solid tumours. The section 2 of the Package Leaflet is updated accordingly. In addition, final results of the GO29665 study are submitted in line with Article 46 of Regulation (EC) No 1901/2006." Request for Supplementary Information adopted on 31.03.2022.	
Hepcludex - bulevirtide - EMEA/H/C/004854/II/0011, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC in order to remove the existing warnings on 'Increase of bile salts' and 'Administration site reactions', and add them as ADRs in section 4.8 of the SmPC as well as the addition of a new ADR: hypersensitivity reactions (including anaphylactic reaction) and editing existing ADRs following a safety review based on pooled data from clinical trials and post-marketing experience. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to make it in line with the EU QRD template v10.2." Request for Supplementary Information adopted on 31.03.2022.	Request for supplementary information adopted with a specific timetable.
IMCIVREE - setmelanotide - EMEA/H/C/005089/II/0003, Orphan Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, "Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations in patients with renal impairment, based on final results from study RM-493-029, a Phase I, open-label, single-dose study to evaluate the pharmacokinetics of setmelanotide in subjects with varying degrees of renal impairment; with secondary objectives to evaluate the safety and tolerability of a single dose of setmelanotide administered subcutaneously in subjects with varying degrees of renal impairment. The Package Leaflet is updated accordingly." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 27.01.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Imfinzi - durvalumab - EMEA/H/C/004771/II/0034	Request for supplementary information adopted with a specific timetable.

AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes. In addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of the SmPC." Request for Supplementary Information adopted on 22.04.2022, 20.01.2022, 21.10.2021.	See 9.1
Imfinzi - durvalumab - EMEA/H/C/004771/II/0039/G AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 4.2 of the SmPC in order to update the recommendation for dose modification for the adverse reaction myocarditis based on NCCN guideline recommendations (2021) and findings in a Global Patient Safety Database, and update of section 4.8 of the SmPC to further clarify the medical concept of the adverse reaction encephalitis, by revising the footnote of the ADR table for encephalitis." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 24.02.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Jardiance - empagliflozin - EMEA/H/C/002677/II/0062/G Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC with the results of clinical study EMPULSE (1245-0204), a multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensated chronic HF) who have been StabilisEd (EMPULSE). In addition, the MAH took the opportunity to implement editorial changes in the SmPC." Request for Supplementary Information adopted on 22.04.2022, 10.02.2022.	Request for supplementary information adopted with a specific timetable. See 9.1
JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0007 GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.2,	Request for supplementary information adopted with a specific timetable.

4.4 and 4.8 of the SmPC in order to update dose modification recommendations in immune related adverse reactions, amend existing warnings and add further immune-related ADRs to the list of adverse drug reactions (ADRs), with different frequencies, based on data from company sponsored trials and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to remove information on Polysorbate 80 and update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 22.04.2022, 27.01.2022.	
Jyseleca - filgotinib - EMEA/H/C/005113/II/0008 Galapagos N.V., Rapporteur: Kristina Dunder, "C.I.4 - Update of section 4.8 of the SmPC in order to add Lymphopenia to the list of adverse drug reactions (ADRs) with frequency common and update the information on serum phosphate and the experience from the long-term extension studies based on interim results from study GS-US-417-0304 (FINCH 4); this is a Multicenter, Double-Blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 22.04.2022, 13.01.2022, 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Kineret - anakinra - EMEA/H/C/000363/II/0087 Swedish Orphan Biovitrum AB (publ), Rapporteur: Thalia Marie Estrup Blicher, "C.I.13: Submission of the final report from study SAVE-MORE, as requested as part of procedure EMEA/H/C/000363/II/086. This is a prospective, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of the early start of anakinra treatment guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 patients over 28 days as measured by the ordinal scale of the 11-point WHO-CPS." Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Kovaltry - octocog alfa - EMEA/H/C/003825/II/0038 Bayer AG, Rapporteur: Kristina Dunder, PRAC	Request for supplementary information adopted with a specific timetable.

Rapporteur: Brigitte Keller-Stanislawski, "Update of the SmPC sections 4.8 and 5.1 to include data from the LEOPOLD Kids Part B (previously submitted as Art 46; an addendum on biomarker data is included in this submission) and extension study results included as part of this submission. In addition, an editorial revision in section 4.2 and a clarification in section 6.5 of the SmPC are proposed. Section 4 of the Package is updated accordingly. A correction of a typo in the Greek product information is also included. The Risk Management Plan for Kovaltry is updated using Revision 2.0.1 of the template format." Request for Supplementary Information adopted on 07.04.2022, 10.02.2022, 02.12.2021.	
Luveris - lutropin alfa - EMEA/H/C/000292/II/0091 Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.1, 4.2, 5.1 and 5.2 of the SmPC in order to update details regarding the definition of severe LH and FSH deficiency, to clarify follicular development as the treatment target and selection of the most adequate Medically Assisted Reproduction procedure for healthcare providers and to clarify the pharmacokinetic and pharmacodynamic properties of the two gonadotropins, in alignment with the variation EMEA/H/C/000714/II/0075 for Pergoveris, based on a systematic literature search and review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Methylthioninium chloride Proveblue - methylthioninium chloride - EMEA/H/C/002108/II/0052/G Provepharm SAS, Rapporteur: Kristina Dunder, "-Update of sections 4.2 and 5.2 of the SmPC in order to change the posology recommendations in patients with renal and hepatic impairment and update of the pharmacokinetic information respectively, based on results from: an open-label, parallel group, population-matched, single-dose study to investigate the influence of renal impairment on the pharmacokinetics of	Request for supplementary information adopted with a specific timetable.

ProvayBlue (Study Report PVP-2016006). The package leaflet and labelling are updated accordingly. The applicant takes this opportunity to update the Product Information according to the QRD template v10.1 and v10.2. - Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with other medicinal products and update the pharmacokinetic information respectively, based on results from: an open-label, randomized, two-period, crossover study to assess the effect of a single dose of methylene blue 5 mg/ml on the pharmacokinetics of the probe drugs midazolam, caffeine, warfarin, omeprazole and dextromethorphan in healthy subjects (Study Report PVP-2016004). The package leaflet and labelling are updated accordingly." Request for Supplementary Information adopted on 22.04.2022, 16.12.2021.	
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0087 Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to add palpitations, asthenia, malaise, feeling cold and blood pressure decreased to the list of adverse drug reactions (ADRs) with frequency "not-known" following the Final Assessment Report for the Post-Authorisation Measure MEAs 024.13 and 0.25.13 (the 2019 Pompe Disease Registry Annual Report) dated 15 October 2020; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 5.1 of the SmPC to update the internet website address of the Pompe Registry." Request for Supplementary Information adopted on 07.04.2022, 20.01.2022.	Request for supplementary information adopted with a specific timetable.
Nimenrix - meningococcal group a, c, w135 and y conjugate vaccine - EMEA/H/C/002226/II/0115 Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang, "Update of section 5.1 of the SmPC, as requested by the CHMP following the conclusion of procedure P46/055, in order to include long-term antibody persistence data from study MenACWY-TT-104: a phase III, randomised, open, controlled, multicentre, primary vaccination study to evaluate the immunogenicity and persistence of 1 and 2	Positive Opinion adopted by consensus on 31.03.2022.

doses of meningococcal conjugate vaccine MenACWY-TT in toddlers (after 1 month and up to 5 years) and to demonstrate non-inferiority of co-administration of MenACWY-TT and 13-valent pneumococcal conjugate vaccine prevenar 13 versus separate administration of the 2 vaccines. The Annex II has been updated accordingly." Opinion adopted on 31.03.2022.	
Prialt - ziconotide - EMEA/H/C/000551/II/0068 ESTEVE Pharmaceuticals GmbH, Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to introduce a new posology regimen. The Package Leaflet to be updated accordingly. In addition, the MAH took the opportunity to update the QRD template to v.10.2 Rev.1 and implement editorial changes in SmPC, PL and Labelling." Request for Supplementary Information adopted on 22.04.2022, 27.01.2022, 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Retsevmo - selpercatinib - EMEA/H/C/005375/II/0010 Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 5.3 of the SmPC in order to reflect the need to monitor open growth plates in adolescent patients based on the results from a non-clinical juvenile toxicity study LOXO-292-TOX-028. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct figures in section 5.1 of the SmPC." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 24.03.2022, 16.12.2021.	Positive Opinion adopted by consensus on 22.04.2022.
Revlimid - lenalidomide - EMEA/H/C/000717/II/0122 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, "Update of section 4.2 of the SmPC to update the dosage for patients with impaired renal function (severe renal impairment and end stage renal disease) for the follicular lymphoma (FL) indication based on additional PK analysis. In addition, the MAH proposed to update the existing warning in section 4.4 of the SmPC to highlight that male patients should not donate semen or sperm during treatment and for at least seven days after the end of treatment in order to align with	Request for supplementary information adopted with a specific timetable.

the Revlimid Annex IID requirements for the patient educational brochures and to align with similar wording in the Imnovid (pomaldiomide) and Thalidomide BMS (thalidomide) SmPCs. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 22.04.2022.	
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0014 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "C.I.4 - Update of section 5.1 of the SmPC in order to update efficacy information based on interim results (week 156) from studies M14-465 and M13-545; these are randomized phase 3, double blind studies to evaluate the long-term safety, tolerability and efficacy of upadacitinib in subjects with Rheumatoid Arthritis." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 22.04.2022.
RYBREVANT - amivantamab - EMEA/H/C/005454/II/0001 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add hypokalaemia and hypomagnesaemia to the list of adverse drug reactions (ADRs), with the frequency common, based on an updated analysis of data submitted during the marketing authorisation procedure. The Package Leaflet is updated accordingly. In addition, the MAH proposed to update the current information in section 4.2 of the SmPC to improve clarity and provide more specific guidance. The MAH also took the opportunity to introduce editorial changes in section 4.8 of the SmPC." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0051 Addmedica S.A.S., Rapporteur: Karin Janssen van Doorn, "C.I.3.b Update of section 5.1 of the SmPC with the available paediatric data from the studies NOHARM and Escort HU according to the PAM-Leg 34." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 22.04.2022.

on 13.01.2022.	
Somavert - pegvisomant - EMEA/H/C/000409/II/0102 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 5.1 of the SmPC in order to include details on insulin sensitivity based on the results of the ACROSTUDY (A6291010) and additional literature. In addition, the MAH took the opportunity to introduce editorial changes to the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Spikevax - elasomeran - EMEA/H/C/005791/II/0057 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly." Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable. See 9.1
Sprycel - dasatinib - EMEA/H/C/000709/II/0083 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Thalia Marie Estrup Blicher, "Submission of the final report from study CA180226 PK sub-study, as requested in X/0056/G procedure, and the population PK (PPK) analyses conducted to refine the PK characterisation of the dasatinib (BMS-354825) powder for oral suspension (PFOS) in paediatric patients with Philadelphia chromosome positive (Ph+) chronic phase chronic myeloid leukaemia (CP-CML) or Ph+ acute lymphoblastic leukaemia (ALL)." Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052 AstraZeneca AB, Rapporteur: Sol Ruiz, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-	Request for supplementary information adopted with a specific timetable. See 9.1

controlled phase II/III clinical study and supportive literature evidence from studies COV001, RHH-001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information." Request for Supplementary Information adopted on 22.04.2022.	
Vocabria - cabotegravir - EMEA/H/C/004976/II/0011 ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Submission of the final report from study 2021N477482_00. This is an in vitro study to assess the cabotegravir inducing potential on CYP1A2 and 2B6 mRNAs in human hepatocyte cells." Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Xevudy - sotrovimab - EMEA/H/C/005676/II/0001/G Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "C.I.4 - Update of sections 4.4, 5.1 and 5.3 of the SmPC, to include new virology data based on the results from pharmacology studies, describing the conservation of the epitope as well as assessing any susceptibility changes due to either individual amino acid substitutions or emerging variants, including data against Omicron BA.1, BA.2 and BA.3; to include a warning to refer to the uncertainty of the clinical relevance of the observed decrease in "in vitro" neutralisation against Omicron BA.2, and include animal toxicology and pharmacology results observed from the cynomolgus monkey 2-week repeat-dose toxicology study. In addition, the MAH took the opportunity to implement editorial changes in sections 4.2, 4.8, 5.1, 5.2, 6.6 and 9 of the SmPC. The package leaflet is updated accordingly. A.6 - To include the ATC Code J06BD05 in section 5.1 of the Summary of Product Characteristics (SmPC). " Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022. See 9.1
WS2154 **CONTROLOC Control- EMEA/H/C/001097/WS2154/0038** **PANTOLOC Control (SRD)-**	Positive Opinion adopted by consensus on 22.04.2022.

EMEA/H/C/001100/WS2154/0043 **PANTOZOL Control-** **EMEA/H/C/001013/WS2154/0040** **SOMAC Control-** **EMEA/H/C/001098/WS2154/0039** Takeda GmbH, Lead Rapporteur: Romaldas Mačiulaitis, "C.1.4 - Update section 4.8 of the SmPC to update the existing term "Interstitial nephritis" to "Tubulointerstitial nephritis (TIN)" in line with the updated Company Core Data Sheet. In addition, section 4.4 of the SmPC for centralised authorised products is updated with the Excipient warning for Sodium as per EMA guideline EMA/CHMP/302620/2017/EN Rev. 1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the PL and to bring the PI in line with the last QRD template (version 10.1). This procedure also includes NAPs as listed in Annex B." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 24.02.2022, 09.12.2021.	

B.5.3. CHMP-PRAC assessed procedures

Cablivi - caplacizumab - **EMEA/H/C/004426/II/0035, Orphan** Ablynx NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on increased risk of bleeding and add blood and lymphatic system disorders to the list of adverse drug reactions (ADRs) with frequency not known based on a safety evaluation report; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted." Request for Supplementary Information adopted on 07.04.2022, 13.01.2022.	Request for supplementary information adopted with a specific timetable.
Cibinqo - abrocitinib - **EMEA/H/C/005452/II/0001** Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study	Request for supplementary information adopted with a specific timetable.

B7451015. The RMP version v1.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the contact details of the local representatives in the Package Leaflet." Request for Supplementary Information adopted on 07.04.2022.	
CRYSVITA - burosumab - EMEA/H/C/004275/II/0028, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to update the frequency of the adverse drug reactions, to split immunogenicity data into paediatric and adult populations and to update clinical efficacy in paediatric patients upon request by the CHMP, following PAM procedures P46/006, P46/007 and type II variations II/04 and II/10/G, based on the final results from studies UX023-CL201, UX023-CL205 and UX023-CL301. In addition, the MAH proposes to delete the remaining specific obligation for study UX023-CL205 from the Annex II and requests the switch from a conditional MA to standard MA. The Package Leaflet was updated accordingly. The RMP version 5.0 has also been submitted." Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0015/G International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Jan Neuhauser, "Submission of the four addenda from studies IPM 032, MTN-025, IPM 007 and MTN-015 listed as category 3 studies in the RMP. The data presented in the addenda are the results of retrospective next generation sequencing (NGS) and phenotype susceptibility testing on blood samples to further assess the potential development of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in women with unrecognized or acute HIV-1 infection. The tested samples are all from women who were initially enrolled in the Phase III clinical trials IPM 027 and MTN-020 and then had the option to participate in the open-label	Request for supplementary information adopted with a specific timetable.

extension (OLE) studies IPM 032 and MTN-025. If the women became infected with HIV during any of the trials, they could enrol in the observational studies IPM 007 and MTN-015. The RMP version 0.9 has also been submitted. Additionally, the MAH would like to take the opportunity to update the EMA on other commitments outlined in the RMP as additional risk minimisation measures. These include the development of a Healthcare Professional Guide (HCP Guide) and a User Guide with agreed objectives and key messages." Request for Supplementary Information adopted on 07.04.2022.	
Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0016 International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Jan Neuhauser, "Update of the Annex II for Dapivirine in order to replace the current PAES: Phase IV, open label, multicentre efficacy trial in healthy HIV-negative young women age 18-25 years (IPM 055), listed as a category 1 study in the RMP, with the implementation study: Dapivirine vaginal ring implementation in a real-world setting in young women. An updated RMP version 0.9 was submitted as part of the application." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Descovy - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094/II/0057 Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the clinical study report and supporting modular summaries for study GS-US-311-1269 'Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen' in fulfilment of the milestone for the category 3 additional pharmacovigilance activity to address the safety concern of long-term safety information in adolescents (missing information) as detailed in the Descovy EU Risk Management Plan (RMP). The RMP version 6.1 has also been submitted."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 07.04.2022.	
ELZONRIS - tagraxofusp - EMEA/H/C/005031/II/0009, Orphan Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, "Submission of the final report from study 20255431 (CRL-263114) 'Characterization of fixed choroid plexus samples from primate study MPI-2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The RMP version 2.0 has also been submitted." Request for Supplementary Information adopted on 22.04.2022, 13.01.2022.	Request for supplementary information adopted with a specific timetable. See 9.1
EXJADE - deferasirox - EMEA/H/C/000670/II/0082/G Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "C.I.13: Submission of the final report from the Calypso study (CICL670F2202) listed as a category 3 study in the RMP. This is a randomized, openlabel, multicenter, two arm, Phase II study to evaluate treatment compliance, efficacy and safety of deferasirox (granules) in paediatric patients with iron overload. The RMP version 20.0 has also been submitted. C.I.11.b: Submission of an updated RMP version 20.0 which the following changes: to remove the risk of 'medication error' from the Exjade RMP and to remove the information related to the discontinuation of Exjade Dispersible Tablets in the EU." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
IBRANCE - palbociclib - EMEA/H/C/003853/II/0037 Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Submission of an updated RMP version 1.8 in order to remove the Important Potential Risk Hyperglycaemia based on the study results from A5481027, a PAM	Positive Opinion adopted by consensus on 07.04.2022.

adopted at the initial MA; this is a multicentre, randomized, double-blind, phase 3 study of palbociclib plus letrozole versus placebo plus letrozole for the treatment of previously untreated Asian postmenopausal women with ER-positive, HER2-negative advanced breast cancer to evaluate the effect of palbociclib on hyperglycaemia - category 3 study." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 10.02.2022.	
Imraldi - adalimumab - EMEA/H/C/004279/II/0048/G Samsung Bioepis NL B.V., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Ulla Wändel Liminga Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 02.12.2021.	Positive Opinion adopted by consensus on 07.04.2022.
Kisqali - ribociclib - EMEA/H/C/004213/II/0035 Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final Overall Survival (OS) analysis from study A2301 (MONALEESA-2); a Phase III, randomized, double-blind, placebo-controlled, multicentre study of ribociclib in combination with letrozole in postmenopausal women with HR+, HER2–, locoregionally recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease, and based on an updated pooled safety dataset (including the studies MONALEESA-2, MONALEESA-3 and MONALEESA-7). The Package Leaflet was updated accordingly. The study is listed as a category 3 study in the RMP and the submission of the final study report addresses MEA 004. An updated RMP version 6.0 was also submitted." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Nulojix - belatacept - EMEA/H/C/002098/II/0079/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga"1. B.I.a.2.c (Type II) 2. B.I.a.4.z (Type IB)	Positive Opinion adopted by consensus on 07.04.2022.

3. C.I.11.z (Type IB): To update the RMP for Nulojix to version 20.1 to include the new maintenance dose, the new potential risk of medication errors and the updated Direct Healthcare Professional Communication (DHPC) listed as an additional risk minimisation measure. This change has been agreed by the CHMP in the outcome of procedure EMEA/H/C/002098/II/0065/G." Opinion adopted on 07.04.2022.	
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0022/G Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on the final study report from study 14-505 (ANNEXA-4). This is a prospective, open-label study of andexanet alfa in patients receiving a factor Xa inhibitor who have acute major bleeding to confirm safety and efficacy in patients with acute major bleeds. The package leaflet was updated accordingly. In addition, the marketing authorisation holder took the opportunity to implement editorial changes in the SmPC and PL. The Annex II (SOBs) has been updated. The revised RMP version 2.5 has also been submitted. Change to the summary of pharmacovigilance system due to change in QPPV." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 24.02.2022, 16.12.2021, 16.09.2021.	Positive Opinion adopted by consensus on 22.04.2022.
Veklury - remdesivir - EMEA/H/C/005622/II/0034/G Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, "Grouping variation to update sections 5.1 and 5.2 of the SmPC as a consequence of the submission of the final component of the Specific Obligation 012 agreed in the renewal of the CMA (EMEA/H/C/005622/R/0015) and listed in the Annex II of the Product Information. This submission includes the ACTT-1 final sequencing and phenotyping analysis and the full virology report including activity against variants. The Package Leaflet is updated accordingly. The RMP version 3.1 has also been submitted." Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.

Xeljanz - tofacitinib - EMEA/H/C/004214/II/0046 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of section 5.3 of the SmPC in order to update safety information on reproductive and developmental toxicity based on final study results from An Oral (Gavage) Juvenile Toxicity Study of CP-690,550 in Sprague Dawley Rats (MEA 022) listed as a cat 3 study in the RMP. The RMP version 26.1 has also been updated. In addition, the MAH is also taking this opportunity to update the contact details of the local representatives in the Package Leaflet." Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0034 Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the final report from study MK-5172-017, listed as a category 3 study in the RMP. This is a Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with Zepatier in a Prior Clinical Trial. The submission of the study report addresses MEA 002.1. The RMP version 5.1 has also been submitted." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
WS2141 **Ozempic-** **EMEA/H/C/004174/WS2141/0024** **Rybelsus-** **EMEA/H/C/004953/WS2141/0018** Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Annika Folin, "Submission of the final report from study NN9535-4386 (SUSTAIN-11), listed as a category 3 study in the RMP. This is a 52-week, multi-centre, multinational, open-label, active controlled, two armed, parallel, randomised trial undertaken to investigate the effect on glycaemic control, body weight, safety and health-related quality of life of once-weekly semaglutide s.c. vs insulin aspart three times daily, both as add-on to metformin and	Positive Opinion adopted by consensus on 07.04.2022.

optimised insulin glargine U100 treatment in subjects with inadequately controlled T2DM. The RMP version 7.0 has also been submitted." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 13.01.2022.	

B.5.4. PRAC assessed procedures

PRAC Led **AJOVY - fremanezumab - EMEA/H/C/004833/II/0029** TEVA GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of an updated RMP version 3.0 in line with the PI changes which were implemented following the assessment of PSUSA/202103 with regards to severe hypersensitivity reactions. The MAH has also taken the opportunity to update the PASS details according to the latest approved PASS protocols." Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0114** GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study EPI-HPV-048 listed as a category 3 study in the RMP. This surveillance study is part of two-phase national HPV surveillance programme that was initiated in the UK by the Health Protection Agency in order to evaluate the impact of HPV vaccination on HPV type replacement. The study aimed to assess the prevalence of type-specific HPV deoxyribonucleic acid (DNA) in young women in England since HPV immunisation using Cervarix was introduced. In addition, the MAH has included the protocol of study EPI-HPV-099 to address the safety concern "Impact and effectiveness against anal lesions and cancer''. The RMP version 25 is considered acceptable." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 10.02.2022.	Positive Opinion adopted by consensus on 07.04.2022.

PRAC Led **Cystadrops - mercaptamine - EMEA/H/C/003769/II/0023, Orphan** Recordati Rare Diseases, Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.11 for RMP: Submission of an updated RMP version 1.4 in order to align with the new RMP format according to GVP Rev.2 and to remove a missing information from the list of safety concerns." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **Defitelio - defibrotide - EMEA/H/C/002393/II/0058/G, Orphan** Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Grouped application including two type II variations as follows: C.I.13: Submission of the final study report of the DEFIFrance registry: a national, post-registration observational study of the long-term safety and health outcome of patients treated with Defitelio, including patients with severe hepatic VOD after HSCT. This study is listed as a category 3 study in the RMP, and the submission of the study report addresses LEG/011.3. In addition, the MAH took the opportunity to provide two errata to the clinical study reports of studies #R09-1425 and #2006-05. Consequential changes to RMP version 9.2 have been implemented. C.I.11: Submission of an updated RMP version 9.2 in order to remove reproductive toxicity as a potential risk." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Evenity - romosozumab - EMEA/H/C/004465/II/0010** UCB Pharma S.A., Rapporteur: Kristina Dunder, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 2.1 in order to add "cardiac arrhythmia" as an important potential risk of romosozumab, update the protocol for	Positive Opinion adopted by consensus on 07.04.2022.

the ongoing post-authorisation safety study (PASS) OP0004 to include cardiac arrhythmias as specific events to monitor, and include a targeted follow-up questionnaire related to cardiac arrhythmias in the RMP Part VII Annex 4, following the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation (EMA/PRAC/265359/2021) dated 06 May 2021. In addition, the MAH is also taking this opportunity to introduce minor changes in the PASS protocols of three studies OP0004, OP0005 and OP0006." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 02.12.2021.	
PRAC Led **Hepcludex - bulevirtide - EMEA/H/C/004854/II/0012, Orphan** Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Update of the RMP in order to replace the non-interventional registry study (MYR-HDV, listed as a category 3 required additional pharmacovigilance activity) with the interventional registry study GS-US-589-6206. In addition, the MAH took this opportunity to update the information on Epidemiology, Clinical Trial Exposure and Post-authorisation experience. RMP version 2.0 is approved with this procedure." Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **Nucala - mepolizumab - EMEA/H/C/003860/II/0048** GlaxoSmithKline Trading Services Limited, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of an updated RMP version 9 to reflect the proposal to stop the enrolment and to close the pregnancy registry "Mepolizumab Pregnancy Exposure Study 200870: a phase IV, prospective, observational, exposure cohort study of pregnancy outcomes in women (category 3 post-authorisation measure in the RMP)". The application also includes details of the proposed enhanced data collection for all pregnancies reported as an alternative." Request for Supplementary Information adopted on 07.04.2022.	Request for supplementary information adopted with a specific timetable.

PRAC Led **OFEV - nintedanib - EMEA/H/C/003821/II/0046** Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur: Nikica Mirošević Skvrce, PRAC-CHMP liaison: Selma Arapovic Dzakula, "Update of the RMP to version 11.1 in order to fulfil a request made in the renewal (EMEA/H/C/003821/R/0025) to remove the following safety concerns (Modules SIV, SVII, SVIII; Parts III, V, VI; Appendices 4, 8) in line with GVP module V (Rev. 2): 1 - Important identified risks: Diarrhoea, Liver enzyme and bilirubin elevations; 2 - Important potential risks: Treatment of pregnant women and teratogenicity, Cardiac failure; 3 - Missing information: Treatment of patients with moderate or severe hepatic impairment (Child Pugh B/C), Treatment of Black patients, Treatment of patients with healing wounds, Treatment of patients with severe renal impairment or end-stage renal disease, Treatment of patients receiving full-dose therapeutic anticoagulation, and Treatment of breastfeeding women." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **Olumiant - baricitinib - EMEA/H/C/004085/II/0031** Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "C.I.4 - Update of section 4.4 of the SmPC in order to add new warnings on Major Adverse Cardiac Events (MACE) and amend existing warning on Malignancy and Venous thromboembolism (VTE) following the request made in PSUSA (EMEA/H/C/PSUSA/00010578/202102) and based on interim results from study I4V-MC-B023; this is a retrospective observational study to compare baricitinib relative to the standard of care. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted. In addition, the MAH has submitted a proposal for a DHPC and communication plan."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 22.04.2022, 13.01.2022.	
PRAC Led **Otezla - apremilast - EMEA/H/C/003746/II/0039** Amgen Europe B.V., Rapporteur: Peter Kiely, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13- Submission of the final study report (CSR) from UK Clinical Practice Research Database (CPRD), listed as a category 3 study in the RMP. This is an observational study to assess the long-term data of apremilast in patients with psoriasis and psoriatic arthritis. The RMP version 14.1 is accepted." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 13.01.2022, 30.09.2021.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **Rapamune - sirolimus - EMEA/H/C/000273/II/0184** Pfizer Europe MA EEIG, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from non-interventional study B1741224, A Population Based Cohort Study to Monitor the Safety and Effectiveness of Sirolimus in Patients With Sporadic Lymphangioleiomyomatosis (S-LAM), designated as a category 3 PASS." Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **Xeljanz - tofacitinib - EMEA/H/C/004214/II/0044** Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "C.I.3.b - Update of sections 4.4, 4.8 and 5.1 to add warnings and safety data on serious infections, viral reactivation, non-melanoma skin cancer and fractures. This is based on the final results from study A3921133 listed as a category 3 study in the RMP; this is a post-authorisation safety study conducted to evaluate the safety of tofacitinib 5 mg and 10 mg compared to TNFi in adults' subjects aged ≥50 years with moderately or severely active RA and with at least 1 additional CV risk factor. The Package Leaflet is updated accordingly. The RMP version 21.1 has also been submitted.	Request for supplementary information adopted with a specific timetable.

In addition, the MAH took the opportunity to update the Outer carton (section 4 for oral solution) to include a total volume of 240 mL as requested following the completion of the procedure EMEA/H/C/004214/X/0024/G." Request for Supplementary Information adopted on 07.04.2022, 02.12.2021.	
PRAC Led **WS2185** **Entresto-** **EMEA/H/C/004062/WS2185/0041** **Neparvis-** **EMEA/H/C/004343/WS2185/0039** Novartis Europharm Limited, Lead PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "To provide an updated RMP to implement the following changes: - Removal of missing information "Paediatric patients" from the Summary of safety concerns in response to the updated assessment report for the Procedure No. EMEA/H/C/WS1830 (20-Nov-2020). - Milestone dates for MAH-sponsored PASS studies were updated. The two concerned studies are PERSPECTIVE (CLCZ696B2320 EU PASS Category 3) and CLCZ696B2015 EU PASS category 3. - Section 8.3.1 (Presentation of important identified risks and important potential risks) was updated and streamlined. - Clinical trial exposure and Post-authorisation exposure has been updated with data cut-off of 31-Jul-2021. - Table 12-1 for the important identified risk "Renal impairment" was updated with "Routine risk minimisation activities recommending specific clinical measures to address the risk" as per SmPC section 4.4. - Targeted follow-up checklists (TFU) for Angioedema and Cognitive impairment were updated." Opinion adopted on 07.04.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 07.04.2022.
PRAC Led **WS2223/G** **Glyxambi-** **EMEA/H/C/003833/WS2223/0043/G**	Positive Opinion adopted by consensus on 07.04.2022.

Jardiance- **EMEA/H/C/002677/WS2223/0066/G** **Synjardy-** **EMEA/H/C/003770/WS2223/0062/G** Boehringer Ingelheim International GmbH, Lead PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Blanca Garcia-Ochoa, "Grouping of two variations as follows: C.I.13: Submission of the final report from study PASS 1245.146 listed as a category 3 study in the RMP. This is 'a 5-year enhanced pharmacovigilance surveillance initiative to survey and characterise spontaneous occurrence and experience of ketoacidotic events in patients treated with empagliflozin-containing products'. The RMP has been updated as a consequence. C.I.11 for RMP: Submission of an updated RMP in order to remove the following safety concerns: - Bone fracture, classified as an important potential risk and - Pregnancy/breast-feeding, classified as missing information. Updated RMP versions 18.0 for Jardiance, 12.0 for Synjardy and 7.0 for Glyxambi were submitted accordingly." Opinion adopted on 07.04.2022.	
PRAC Led **WS2235** **Kisplyx-EMEA/H/C/004224/WS2235/0050** **Lenvima-** **EMEA/H/C/003727/WS2235/0046** Eisai GmbH, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.8 of the SmPC of Lenvima and Kisplyx in order to add colitis to the list of ADRs with frequency uncommon, following PRAC Signal assessment of colitis with lenvatinib (EPITT no: 19691). The Package Leaflets are updated accordingly." Opinion adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.04.2022.

B.5.5. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel - **EMEA/H/C/004090/II/0050, Orphan, ATMP** Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 13.04.2022.	
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0052, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 22.04.2022, 13.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
Luxturna - voretigene neparvovec - EMEA/H/C/004451/II/0026/G, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro Opinion adopted on 22.04.2022, 13.04.2022. Request for Supplementary Information adopted on 21.01.2022.	Positive Opinion adopted by consensus on 22.04.2022.
WS2194 **Tecartus-** **EMEA/H/C/005102/WS2194/0018** **Yescarta-** **EMEA/H/C/004480/WS2194/0048** Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 10.02.2022.	Positive Opinion adopted by consensus on 22.04.2022.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2168 **Lyrica-EMEA/H/C/000546/WS2168/0114** **Pregabalin Pfizer-** **EMEA/H/C/003880/WS2168/0043** Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "To update SmPC sections 4.4 and 4.8 to reflect new data on suicidal ideation following the review of the data provided in LEG 007 and 054. The package leaflet has been updated accordingly." Opinion adopted on 22.04.2022. Request for Supplementary Information adopted on 17.02.2022.	Positive Opinion adopted by consensus on 22.04.2022.

WS2202/G **Comtan-** **EMEA/H/C/000171/WS2202/0059/G** **Comtess-** **EMEA/H/C/000170/WS2202/0062/G** **Corbilta-** **EMEA/H/C/002785/WS2202/0028/G** **Entacapone Orion-** **EMEA/H/C/002440/WS2202/0021/G** **Levodopa/Carbidopa/Entacapone Orion-** **EMEA/H/C/002441/WS2202/0036/G** **Stalevo-** **EMEA/H/C/000511/WS2202/0098/G** Orion Corporation, Lead Rapporteur: Outi Mäki-Ikola Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
WS2213/G **Aprovel-** **EMEA/H/C/000141/WS2213/0189/G** **Karvea-** **EMEA/H/C/000142/WS2213/0191/G** sanofi-aventis groupe, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 31.03.2022. Request for Supplementary Information adopted on 17.02.2022.	Positive Opinion adopted by consensus on 31.03.2022.
WS2226/G **Aflunov-** **EMEA/H/C/002094/WS2226/0076/G** **Foclivia-** **EMEA/H/C/001208/WS2226/0074/G** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
WS2230 **Ebymect-** **EMEA/H/C/004162/WS2230/0056** **Xigduo-EMEA/H/C/002672/WS2230/0066** AstraZeneca AB, Lead Rapporteur: Kristina Dunder Opinion adopted on 22.04.2022.	Positive Opinion adopted by consensus on 22.04.2022.
WS2233 **Hexacima-** **EMEA/H/C/002702/WS2233/0127** **Hexyon-** **EMEA/H/C/002796/WS2233/0131** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-	Positive Opinion adopted by consensus on 22.04.2022.

Berghaus Opinion adopted on 22.04.2022.	
WS2234/G **Ebymect-** **EMEA/H/C/004162/WS2234/0055/G** **Edistride-** **EMEA/H/C/004161/WS2234/0052/G** **Forxiga-** **EMEA/H/C/002322/WS2234/0073/G** **Qtern-** **EMEA/H/C/004057/WS2234/0034/G** **Xigduo-** **EMEA/H/C/002672/WS2234/0065/G** AstraZeneca AB, Lead Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
WS2236/G **Aflunov-** **EMEA/H/C/002094/WS2236/0077/G** **Foclivia-** **EMEA/H/C/001208/WS2236/0075/G** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.
WS2237 **Copalia HCT-** **EMEA/H/C/001159/WS2237/0098** **Dafiro HCT-** **EMEA/H/C/001160/WS2237/0100** **Exforge HCT-** **EMEA/H/C/001068/WS2237/0097** Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, "To update sections 4.4 and 4.8 of the SmPC in line with assessment of a PSUSA/00001662/202101 procedure on hydrochlorothiazide/spironolactone regarding the risk of acute respiratory distress syndrome (ARDS) linked to hydrochlorothiazide. The Package Leaflet has been updated in accordance." Opinion adopted on 31.03.2022.	Positive Opinion adopted by consensus on 31.03.2022.
WS2238 **Hukyndra-** **EMEA/H/C/005548/WS2238/0001** **Libmyris-** **EMEA/H/C/005947/WS2238/0001**	Positive Opinion adopted by consensus on 22.04.2022.

STADA Arzneimittel AG, Lead Rapporteur: Outi Mäki-Ikola Opinion adopted on 22.04.2022.	
WS2248/G **Aflunov-** **EMEA/H/C/002094/WS2248/0078/G** **Foclivia-** **EMEA/H/C/001208/WS2248/0076/G** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani Request for Supplementary Information adopted on 22.04.2022.	Request for supplementary information adopted with a specific timetable.

B.5.9. Information on withdrawn type II variation / WS procedure

Edurant - rilpivirine - EMEA/H/C/002264/II/0040 Janssen-Cilag International N.V., Rapporteur: Paula Boudewina van Hennik, "Update of section 4.8 of the SmPC in order to remove several of the treatment emergent clinical laboratory abnormalities from the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Withdrawal request submitted on 20.04.2022.	The MAH withdrew the procedure on 20.04.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

sars-cov-2 prefusion spike delta tm protein, recombinant - EMEA/H/C/005754 Active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

in vitro diagnostic medical device - EMEA/H/D/006065

In-vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma
Request for Supplementary Information adopted on 24.03.2022.

B.6.4. Annual Re-assessments: timetables for adoption

Lamzede - velmanase alfa -
EMEA/H/C/003922/S/0025, Orphan
Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Cuprior - trientine -
EMEA/H/C/004005/R/0018
Orphalan, Rapporteur: Jayne Crowe, Co-Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ana Sofia Diniz Martins

Miglustat Gen.Orph - miglustat -
EMEA/H/C/004366/R/0022
Gen.Orph, Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ulla Wändel Liminga

NexoBrid - concentrate of proteolytic enzymes enriched in bromelain -
EMEA/H/C/002246/R/0056, Orphan
MediWound Germany GmbH, Rapporteur: Janet Koenig, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Martin Huber

PREVYMIS - letermovir -
EMEA/H/C/004536/R/0027, Orphan
Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Kirsti Villikka

TOOKAD - padeliporfin -
EMEA/H/C/004182/R/0019
STEBA Biotech S.A, Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Maia Uusküla

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Dupixent - dupilumab - EMEA/H/C/004390/II/0060 sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of atopic dermatitis in paediatric patients from 6 months to <6 years of age based on final results from study R668-AD-1539; this is a phase 2/3 study investigating the pharmacokinetics, safety and efficacy of dupilumab in patients aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted."
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0073 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation, based on final results from the category 3 study PCI-32765MCL3002 (SHINE); this is a randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with BR in subjects with newly diagnosed MCL. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 19.1 of the RMP has also been submitted."
Kerendia - finerenone - EMEA/H/C/005200/II/0001/G Bayer AG, Rapporteur: Kristina Dunder, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes, based on results from study 17530 (FIGARO-DKD); a randomized, double-blind, placebo-controlled,

parallel-group, multicentre, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC is being updated and the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC. The updated RMP version 2.1 has also been submitted. Update of the SmPC section 5.2 based on the results of study 21429, a phase 1 drug interaction study of finerenone with rosuvastatin. The CSR PH-42032 was already submitted within the response to Day 180 List of Outstanding Issues of the initial MAA. Submission of the results of study 21325, a phase 1 bioequivalence study assessing BE between finerenone 2 x 10 mg tablets and 20 mg tablet in Japanese healthy male adult participants (required by the Japanese PMDA)."	
NUBEQA - darolutamide - EMEA/H/C/004790/II/0009 Bayer AG, Rapporteur: Alexandre Moreau, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Jan Neuhauser, "Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel, based on final results from study 17777 (ARASENS); this is a randomized, double-blind, placebo-controlled Phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is also requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	

NUVAXOVID - sars-cov-2, spike protein, recombinant, expressed in sf9 cells derived from spodoptera frugiperda - EMEA/H/C/005808/II/0009

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include use in adolescents 12 to 17 years of age for Nuvaxovid, based on data from study 2019nCoV-301, a Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to evaluate the efficacy, safety and immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M Adjuvant in Adult Participants ≥ 18 Years with a Paediatric Expansion in Adolescents (12 to < 18 Years); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

OPDIVO - nivolumab - EMEA/H/C/003985/II/0117

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include Opdivo in combination with platinum-based chemotherapy for neoadjuvant treatment of adult patients with resectable stage IB-IIIA non-small cell lung cancer (NSCLC), based on results from study CA209816; a randomised, open-label, phase 3 trial of nivolumab plus ipilimumab or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in early-stage NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 27.0 of the RMP has also been submitted."

Xydalba - dalbavancin - EMEA/H/C/002840/II/0043

Allergan Pharmaceuticals International Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene, "Extension of indication to the paediatric population (aged 3 months to < 18 years) for the treatment of ABSSSI based on the interim results from the safety and efficacy Phase 3 study DUR001-306, together with data

from 3 Phase 1 PK studies (A8841004, DUR001-106, and DAL-PK-02). Consequently, the sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC were updated. The Package Leaflet has been updated accordingly.
In addition, the applicant has taken the opportunity to make minor editorial amendments and QRD updates (v10.2) to the SmPC/PIL. Version 7.0 of the RMP has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Abevmy - bevacizumab - EMEA/H/C/005327/II/0009
Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus

Alymsys - bevacizumab - EMEA/H/C/005286/II/0010
Mabxience Research SL, Rapporteur: Christian Gartner

BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0047/G, Orphan
Amgen Europe B.V., Rapporteur: Alexandre Moreau

Brintellix - vortioxetine - EMEA/H/C/002717/II/0033
H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0124/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0125/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0126/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0135
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Hizentra - human normal immunoglobulin -

EMEA/H/C/002127/II/0136/G
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0050
Janssen-Cilag International N.V., Rapporteur: Christophe Focke

NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0117
Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik

Oyavas - bevacizumab - EMEA/H/C/005556/II/0009/G
STADA Arzneimittel AG, Duplicate, Duplicate of Alymsys, Rapporteur: Christian Gartner

Ruxience - rituximab - EMEA/H/C/004696/II/0011
Pfizer Europe MA EEIG, Rapporteur: Paula Boudewina van Hennik

Spectrila - asparaginase - EMEA/H/C/002661/II/0029
medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop

TAKHZYRO - lanadelumab - EMEA/H/C/004806/II/0030/G, Orphan
Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder

Temozolomide SUN - temozolomide - EMEA/H/C/002198/II/0037
Sun Pharmaceutical Industries Europe B.V., Generic, Generic of Temodal, Rapporteur: Filip Josephson

Vaniqa - eflornithine - EMEA/H/C/000325/II/0056
Almirall S.A, Rapporteur: Peter Kiely

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0097
MCM Vaccine B.V., Rapporteur: Christophe Focke

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S

[recombinant]) -
EMEA/H/C/005675/II/0071
AstraZeneca AB, Rapporteur: Sol Ruiz

Ziextenzo - pegfilgrastim -
EMEA/H/C/004802/II/0019
Sandoz GmbH, Rapporteur: Andrea Laslop

WS2245
Hexacima-
EMEA/H/C/002702/WS2245/0129
Hexyon-
EMEA/H/C/002796/WS2245/0133
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Avonex - interferon beta-1a -
EMEA/H/C/000102/II/0193
Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2 and 4.4 of the SmPC in order to update safety information for the paediatric population based on the final results of the Tecfidera Paediatric study (109MS306) (CONNECT - part 1), submitted as part of the PAM procedure P46/089, availability of data from published literature and post-marketing data from Biogen global safety database; the Package Leaflet is updated accordingly."

Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) -
EMEA/H/C/002333/II/0112
GSK Vaccines S.r.l, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to add information based on Real World Evidence (RWE) on vaccination impact and effectiveness from literature references available up to July 2021. The MAH also proposes to remove the existing statement related to paediatric studies in section 5.1 of the SmPC. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."

Darzalex - daratumumab -
EMEA/H/C/004077/II/0060/G, Orphan
Janssen-Cilag International N.V., Rapporteur: Thalia Marie Estrup Blicher, "C.I.4: Update of section 5.1 of the SmPC to include the final

overall survival (OS) results based on the final OS analysis for pivotal study 54767414MMY3003 (MMY3003). MMY3003 (Pollux) is an open-label, randomized, active-controlled Phase III study that compared treatment with DARZALEX 16 mg/kg in combination with lenalidomide (DRd) to treatment with lenalidomide and low-dose dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma who had received at least one prior therapy. C.I.4: Update of section 5.1 of the SmPC to include the final overall survival (OS) results based on the final OS analysis for pivotal studies 54767414MMY3004 (MMY3004). MMY3004 (Castor) is a Phase III, multicentre, randomized, open-label, active-controlled study comparing daratumumab in combination with bortezomib and dexamethasone (DVd) with bortezomib and dexamethasone (Vd) in subjects with relapsed or refractory multiple myeloma. In addition, the MAH took the opportunity to implement some editorial changes."	
Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0029 ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC based on interim results from study 204862 (TANGO); this is an on-going 200-week, Phase III, randomized, open-label, active controlled, multicentre, parallel-group study, evaluating the efficacy, safety, and tolerability of switching to the Dovato fixed dose combination tablet (DTG/ 3TC FDC) in HIV-1 infected adults who are virologically suppressed. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."	
Dynastat - parecoxib - EMEA/H/C/000381/II/0085 Pfizer Europe MA EEIG, Duplicate, Duplicate of Xapit (SRD), Rapporteur: Jayne Crowe, "Update of section 4.9 of the SmPC in order to amend it with the current medical guidance for acute NSAIDs poisoning/overdose. In addition, the MAH took the opportunity to introduce a minor editorial change to the PI and to update the list of local representatives in the Package Leaflet."	
GONAL-f - follitropin alfa - EMEA/H/C/000071/II/0155	

Merck Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.1, 4.2, 4.4, 5.1, 5.2 and 6.6 of the SmPC to revise the definition of severe LH and FSH deficiency, aligning with current medical guidelines and clinical practice, to clarify follicular development as the treatment target and selection of the most adequate Medically Assisted Reproduction procedure for healthcare providers, and the pharmacokinetic and pharmacodynamic properties of follitropin alfa; and to align with the Product Information of Pergoveris as previously assessed by the CHMP in procedure EMA/H/C/000714/II/0075. The package leaflet is updated accordingly. In addition, the applicant has taken the opportunity to improve the Instructions for Use (IFU) layout and to implement the Medical Device Regulation in the IFU."	
HBVAXPRO - hepatitis B vaccine (rDNA) - EMEA/H/C/000373/II/0076 Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller-Berghaus, "Update of section 5.1 of the SmPC in relation to the duration of protection over 9 years (re-challenge) in healthy subjects following procedure EMEA/H/C/000373/P46/061. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and the Package Leaflet."	
IBRANCE - palbociclib - EMEA/H/C/003853/II/0038/G Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, "C.I.4: Update of section 5.3 of the SmPC in order to update the primary target organ findings and development toxicity wording. In addition, the MAH took the opportunity to update the list of local representatives (Belgium, Luxembourg, Germany and the Netherlands) in the Package Leaflet. A.6: Update of Palbociclib ATC code based on the last revised classification of the Cyclin-dependent kinase (CDK) inhibitors made by the WHO."	
INREBIC - fedratinib - EMEA/H/C/005026/II/0010/G, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur:	

Sonja Hrabcik, "Update of section 4.4 of the SmPC in order to add new warnings on major adverse cardiac events (MACE), thrombosis and secondary malignancies. The updates pertain to three signals, assessed by the FDA, which were identified with another JAK inhibitor (tofacitinib) indicated in rheumatoid arthritis; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Keytruda - pembrolizumab - EMEA/H/C/003820/II/0122

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning for 'Hypoparathyroidism' and to add it to the list of adverse drug reactions (ADRs) with frequency rare based on literature references; the Package Leaflet is updated accordingly."

Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0025

AstraZeneca AB, Rapporteur: Romaldas Mačiulaitis, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information based on final report for interventional study D9480C00012, "A Two-Cohort, Randomised Sequence, Crossover, Open-label Study to Assess the Effect of a Single Dose of Sodium Zirconium Cyclosilicate (SZC) on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects".
The Package Leaflet is updated accordingly.
In addition, the MAH is also taking this opportunity to update the contact details of the local representatives in the Package Leaflet."

Lucentis - ranibizumab - EMEA/H/C/000715/II/0098

Novartis Europharm Limited, Rapporteur: Kristina Dunder, "Update of section 4.6 of the SmPC in order to update information on breastfeeding following the PRAC Recommendation (EMEA/H/C/PSUSA/00002609/202010) based on a cumulative assessment of pre-clinical studies, pharmacokinetic data, published literature and post-marketing spontaneous reports. The Package Leaflet is updated

accordingly."

Neuraceq - florbetaben (18F) - EMEA/H/C/002553/II/0038

Life Radiopharma Berlin GmbH, Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4 and 5.1 of the SmPC in order to include information on the possibility of quantitative assessment as an adjunct to visual read of Neuraceq scans based on final results from study titled "Evaluation of quantitative assessment of florbetaben (18F) PET scans as an adjunct to visual assessment". This is a retrospective data analysis to evaluate florbetaben PET quantification as an adjunct to the approved visual assessment method."

Onivyde pegylated liposomal - irinotecan hydrochloride trihydrate - EMEA/H/C/004125/II/0031, Orphan

Les Laboratoires Servier, Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC in order to update the duration of effective contraception in women with childbearing potential in line with the CHMP Safety working party (SWP) recommendations on the duration of contraception following the end of treatment with a genotoxic drug and to add a statement about the preservation of gametes. In addition, the MAH took the opportunity to introduce minor changes to section 6.6 of the SmPC to provide clarification regarding the size of the needle to be used for the preparation of the infusion prior to administration. The Package Leaflet is updated accordingly."

Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0008

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of the final report from study PMAR-EQDD-C467a-DP4-1323, listed as a legally binding measure. This is an updated population pharmacokinetics module results including PK data from the patients enrolled in the EPIC-HR study of Paxlovid."

Regkirona - regdanvimab - EMEA/H/C/005854/II/0004

Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC to include in vitro neutralisation activity of regdanvimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern based on report REP-ND22-047."

Remicade - infliximab - EMEA/H/C/000240/II/0235

Janssen Biologics B.V., Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add 'Orbital Apex Syndrome' to the list of adverse drug reactions (ADRs) with frequency very rare based on a cumulative review and literature references; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI according to the QRD template version 10.2 rev.1."

RINVOQ - upadacitinib - EMEA/H/C/004760/II/0019

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Update of section 4.5 of the SmPC in order to add information about drug interaction with grapefruit as a CYP3A4 inhibitor based on literature references; the Package Leaflet is updated accordingly."

Rozlytrek - entrectinib - EMEA/H/C/004936/II/0010

Roche Registration GmbH, Rapporteur: Armando Genazzani, "Submission of the final report from study (RO7102122) to address the non-clinical recommendation issued within the initial MAA. This is an in-vitro study for the evaluation of entrectinib against novel clinically-relevant NTRK fusions using the Ba/F3 cell line."

SARCLISA - isatuximab - EMEA/H/C/004977/II/0014

sanofi-aventis groupe, Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on Infections by adding herpes zoster prophylaxis as antiviral prophylaxis, following FDA post-market survey and request to update the US PI based on a cumulative assessment of Sanofi global PV database and scientific literature. The Package Leaflet is updated accordingly."

TRODELVY - sacituzumab govitecan -

EMEA/H/C/005182/II/0008
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from the repeat-dose toxicity study (3277-001) with the novel excipient 2-(N-morpholino) ethane sulfonic acid (MES). This is a non-clinical toxicology study titled "A 1-Month Study of MES by Intravenous Injection in Sprague Dawley Rats with a 1- and a 7-Day Post Dose Observation Periods"."

Veklury - remdesivir - EMEA/H/C/005622/II/0036
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of sections 4.4 and 5.1 of the SmPC in order to update information regarding the baseline serostatus of patients included in the study GS US 540 9012 (Phase 3, randomized, double blind, placebo controlled study to evaluate RDV treatment of COVID 19 in an outpatient setting) listed as a recommendation (number 24) within the procedure EMA/005622/II/0016 that led to the extension of indication of remdesivir to adults with confirmed COVID 19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease."

Vyepti - eptinezumab - EMEA/H/C/005287/II/0001
H. Lundbeck A/S, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to add infusion-related reaction to the list of adverse drug reactions (ADRs) with frequency common, and to update the frequency of anaphylactic reaction to uncommon (from rare) based on a signal assessment conducted by the MAH. The Package Leaflet is updated accordingly."

Wegovy - semaglutide - EMEA/H/C/005422/II/0003/G
Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to update the description of the pharmacodynamic effects and clinical efficacy and safety based on final results from interventional studies: Trial 4378 (STEP 5) which compared the two-year effect of semaglutide 2.4 mg once weekly versus placebo; Trial 4576 (STEP 8) which compared semaglutide s.c. 2.4 mg once weekly to

liraglutide s.c. 3.0 mg once daily and Trial 4373 extension (STEP 1ext) which explored the change in body weight, cardiovascular risk factors and glucose metabolism in subjects who completed 68 weeks of treatment (semaglutide 2.4 mg or placebo) followed by a 52-week off-treatment period."

WS2241/G
Advagraf-
EMEA/H/C/000712/WS2241/0065/G
Modigraf-
EMEA/H/C/000954/WS2241/0039/G
Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, "Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on the adverse reaction Thrombotic microangiopathy (TMA) based on a cumulative review of fatal cases of TMA during treatment with tacrolimus, requested by the PRAC following the assessment of the PSUR (EMEA/H/C/00002839/202103).
Update of section 4.5 of the SmPC in order to add the drug-drug interaction between tacrolimus and caspofungin based on post-marketing safety report and literature.
Update of section 5.2 of the SmPC in order to add that tacrolimus is metabolised by the cytochrome P450-3A5 (CYP3A5) based on post-marketing safety report and literature.
The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement some editorial changes."

B.6.10. CHMP-PRAC assessed procedures

Carbaglu - carglumic acid -
EMEA/H/C/000461/II/0044
Recordati Rare Diseases, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of sections 4.2 and 4.4 of the SmPC in order to include information on the impact of renal impairment on systemic exposures to Carbaglu following a FDA request, based on final results from study A Phase I, Multicentre, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Carbaglu in Subjects with Normal and Varying Degrees of Impaired Renal Function.
The Package Leaflet is updated accordingly.
The RMP version 2.2 has also been submitted.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0047, Orphan

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Annika Folin, "Submission of the final report from study BO21223/GALLIUM listed as a category 3 study in the RMP. This is an open-label, international, multicentre, randomized, Phase III study to investigate the efficacy and safety of obinutuzumab administration at standard infusion rate plus chemotherapy followed by obinutuzumab maintenance therapy for responders (G-chemo arm) compared with rituximab plus chemotherapy followed by rituximab maintenance therapy for responders (R-chemo arm) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (iNHL).The RMP version 9.0 has also been submitted."

IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0059, Orphan

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update information and amend the frequencies of adverse drug reactions (ADRs) based on the final results from study CSL654_3003 listed as a category 3 study in the RMP; this is an open-label, multicentre, uncontrolled study to evaluate the safety, pharmacokinetics and clinical response of rIX-FP with regard to the prevention and treatment of bleeding in previously untreated patients (PUPs) with Haemophilia B. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet."

Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0024, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim

results from clinical study VX17-445-105 (study 105) listed as a category 3 study in the RMP; this is a Phase III, open label extension study to evaluate the long-term safety and efficacy of ELX/TEZ/IVA in CF subjects homozygous for F508del (F/F genotype) or heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes). The RMP version 6.1 has also been submitted. In addition, the MAH took the opportunity to implement minor corrections to the SmPC (sections 5.3 and 6.5); as well as editorial changes to the SmPC and the Package Leaflet."	
Opsumit - macitentan - EMEA/H/C/002697/II/0046, Orphan Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of sections 4.6 and 5.3 of the SmPC in order to introduce additional data on male fertility based on literature search and global safety database. The RMP version 13.1 has also been submitted."	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0007 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Submission of the final report from study C4671010 listed as a category 3 study in the RMP. This is a phase I, non-randomized, open label study to assess the pharmacokinetics, safety and tolerability of PF-07321332 boosted with ritonavir in adults with moderate hepatic impairment and individuals with normal hepatic function. The RMP version 2.0 has also been submitted."	
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0020/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Hypersensitivity' and add it to the list of adverse drug reactions (ADRs) with frequency not known. The MAH also proposed to update section 4.8 of the SmPC in order to add	

'Non-Melanoma Skin Cancer (NMSC)' to the list of adverse drug reactions (ADRs) with frequency uncommon. The Package Leaflet has been updated accordingly. The RMP version 9.0 has also been submitted."

Scintimun - besilesomab - EMEA/H/C/001045/II/0015

CIS BIO International, PRAC Rapporteur: Maria del Pilar Rayon, "Submission of the final report from the clinical study AG-2012 - Non interventional controlled survey on the impact of Scintimun administered for scintigraphic imaging on diagnostic thinking and management of patient with suspicion of peripheral osteomyelitis, listed as a category 3 study in the RMP - MEA 08.4. An updated RMP version 15 was submitted."

Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0038

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Ilaria Baldelli, "Submission of the final week 192 report from study GS-US-320-3912; 'A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF)–containing Regimens in Subjects with Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant', listed as a category 3 study in the RMP.
The RMP version 8.1 has also been submitted."

B.6.11. PRAC assessed procedures

PRAC Led

HEPLISAV B - hepatitis B surface antigen - EMEA/H/C/005063/II/0015

Dynavax GmbH, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from the study HBV-26: Post-Marketing Observational Surveillance Study to Evaluate the Incidence of New-Onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis, listed as a category 3 post-authorisation safety study (PASS) in the RMP.
This is a post-marketing observational surveillance study comparing the incidence of

new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in recipients of HEPLISAV B with recipients of another hepatitis B vaccine.
The RMP version 1.3 has also been submitted."

PRAC Led
Jinarc - tolvaptan - EMEA/H/C/002788/II/0036
Otsuka Pharmaceutical Netherlands B.V., PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of an updated RMP version 15.0 in order to reflect the outcome of the substantial amendment to the protocol of the category 1 PASS study (156-12-299) as concluded in (PSA/S/0078.1). The Annex II is updated accordingly. In addition, the MAH took the opportunity to correct an oversight/editorial error in the Package Leaflet relevant to (II/0033/G)."

PRAC Led
Rotarix - rotavirus vaccine (live, oral) - EMEA/H/C/000639/II/0125
GlaxoSmithKline Biologicals S.A., PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study EPI-ROTA-052 BOD EU SUPP (201433) listed as a category 3 study in the RMP. This is an Observational community-based strain surveillance study to monitor the potential emergence and spread of novel RV strains throughout Europe. The RMP version 23 has also been submitted."

PRAC Led
Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0040
Pfizer Europe MA EEIG, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from PASS B1971052 - A Pregnancy and Birth Outcome Assessment in a Population-based Cohort After Exposure to Trumenba, listed as a category 3 study in the RMP. Study B1971052 is a population-based, non-interventional cohort study utilising administrative healthcare claims data."

PRAC Led
VIZAMYL - flutemetamol (18F) -

EMEA/H/C/002557/II/0029
GE Healthcare AS, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study (GE067-027) listed as a category 3 study in the RMP in addition to a comprehensive root-cause analysis on the contributing factors having an impact on reader performance as requested by PRAC. This is a non-interventional post-authorisation safety study (PASS) to evaluate the effectiveness of VIZAMYL reader training in Europe. The RMP version 3.1 has also been submitted and updated to reflect the completion of study GE067-028, previously assessed in MEA 003.3."

B.6.12. CHMP-CAT assessed procedures

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and work-sharing procedures of type I variations

WS2242
Mircera-EMEA/H/C/000739/WS2242/0090
NeoRecormon-
EMEA/H/C/000116/WS2242/0117
Roche Registration GmbH, Lead Rapporteur: Martina Weise

WS2256/G
Copalia-
EMEA/H/C/000774/WS2256/0124/G
Copalia HCT-
EMEA/H/C/001159/WS2256/0099/G
Dafiro-
EMEA/H/C/000776/WS2256/0128/G
Dafiro HCT-
EMEA/H/C/001160/WS2256/0101/G
Exforge-
EMEA/H/C/000716/WS2256/0123/G
Exforge HCT-
EMEA/H/C/001068/WS2256/0098/G
Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher

WS2266
Blitzima-

EMEA/H/C/004723/WS2266/0056 **Truxima-** **EMEA/H/C/004112/WS2266/0059** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz	
WS2267/G **CoAprovel-** **EMEA/H/C/000222/WS2267/0210/G** **Karvezide-** **EMEA/H/C/000221/WS2267/0210/G** sanofi-aventis groupe, Duplicate, Duplicate of Karvezide, Lead Rapporteur: Maria Concepcion Prieto Yerro	
WS2273 **Rixathon-** **EMEA/H/C/003903/WS2273/0055** **Riximyo-** **EMEA/H/C/004729/WS2273/0056** Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, "To update section 6.6 of the SmPC and section 2 of the PL to align the wording with the originator Mabthera, following finalisation of procedure EMEA/H/C/000165/II/0185/G. In addition, the marketing authorisation holder has taken the opportunity to implement minor editorial changes in the PI."	

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 19-22 April 2022 CHMP plenary:

Endocrinology-Gynaecology-Fertility-Metabolism	
Treatment of congenital hyperinsulinism (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Musculoskeletal and connective tissue disorders	
BCX9250 Treatment of fibrodysplasia ossificans progressiva (SME)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Vaccines	
GBS6 (Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine) Prevention of Group B streptococcal invasive disease due to the vaccine serotypes in infants by active immunization of pregnant women	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Dermatology	
Treatment of recessive dystrophic epidermolysis bullosa (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Diagnostic	
Diagnosis of indeterminate renal masses previously identified on CT or MRI as clear cell Renal Cell Carcinoma (ccRCC) or non-ccRCC. (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in April 2022 for May 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address